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ABSTRACT 
Prostate-specific antigen (PSA) is a very useful biomarker for prostate cancer. The PSA 
concentration in circulation increases due to leakage of PSA from cancerous tissue. Normally 
PSA, a serine protease with chymotrypsin-like enzymatic activity, is secreted into seminal fluid 
by the epithelial cells of the prostate. The major physiological function of PSA in seminal fluid 
is to digest semenogelins, which leads to liquefaction of the seminal clot. Several other 
functions have also been suggested for PSA, some of which are associated with cancer. PSA 
exerts antiangiogenic activity, but PSA may also promote tumor growth and metastatic 
dissemination. The aim of the research presented in this thesis was to characterize the 
antiangiogenic and proteolytic activities of PSA. One of the main goals was to elucidate 
whether the enzymatic activity of PSA is a requirement for its antiangiogenic activity. 
The antiangiogenic activity of PSA was studied using an in vitro angiogenesis model 
based on tube formation of human umbilical vein endothelial cells (HUVEC). In this model 
only enzymatically active PSA was able to inhibit angiogenesis. Peptides that stimulate the 
proteolytic activity of PSA enhanced the antiangiogenic activity, while small molecule 
compounds that inhibit PSA abolished this activity. DNA microarray study showed that PSA-
induced changes in the gene expression of HUVECs were small during tube formation, and it 
was not clear whether these changes were primary or secondary to the antiangiogenic activity 
of PSA. The results of this thesis suggest that the antiangiogenic activity of PSA is mediated 
by a proteolytic product generated by PSA. The proteolytic activity of PSA was studied using 
several peptide and protein substrates. Semenogelins are the major physiological substrates of 
PSA and they were shown to be degraded much more rapidly than any other protein substrate 
studied. Nidogen-1, a component of the basement membrane, was identified as a novel 
substrate for PSA by mass spectrometry. However, the cleavage of nidogen-1 did not explain 
the antiangiogenic activity of PSA, since either its fragments or full-length form did not affect 
HUVEC tube formation. Contrary to a previous report, we showed that the antiangiogenic 
activity of PSA was not mediated by angiostatin-like fragments generated by the cleavage of 
plasminogen.  
The results of this thesis established that the proteolytic activity is necessary for the 
antiangiogenic activity of PSA and that the antiangiogenic activity can be enhanced by PSA-
stimulating peptides and abolished by PSA-inhibitors. The comparison of the efficiency of PSA 
to cleave different protein substrates and the identification of nidogen-1 as one of these 
substrates provided new information about the biological role of PSA. The typically slow 
growth of most prostate cancers may be caused by the antiangiogenic activity of PSA, as there 
are high concentrations of active PSA present in prostatic tissue. Therefore, peptides that 
stimulate the antiangiogenic activity of PSA and reduce tumor angiogenesis could be used to 
control prostate cancer growth. 
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INTRODUCTION 
Prostate cancer is the most common non-skin 
cancer in males and the third most common 
cause of cancer death in men in the devel-
oped countries (Jemal et al. 2011). Prostate 
cancer develops slowly and it may take 
decades for the tumor to progress to clinical 
disease (Schmid et al. 1993; Stenman et al. 
1999a). Prostate-specific antigen (PSA) is a 
useful biomarker for prostate cancer, as its 
leakage into circulation, and thus the 
concentration in the blood, increases during 
cancer development (Stenman et al. 2005). 
However, PSA is not cancer-specific since 
its concentration increases also in benign 
prostatic diseases (Stamey et al. 1987).  
Proteases are involved in various 
physiological and pathological processes, 
including cancer development. Increased 
proteolytic activity has been associated with 
cancer progression: proteases facilitate 
tumor cell invasion and metastatic dissemi-
nation by degradation of extracellular matrix 
(ECM) proteins (Hanahan and Weinberg 
2000; Mason and Joyce 2011). Some 
proteases have also tumor growth-inhibiting 
functions, such as induction of apoptosis and 
generation of antiangiogenic fragments from 
ECM components (Lopez-Otin and 
Matrisian 2007; Kessenbrock et al. 2010). 
The proteases of the kallikrein-related 
peptidase (KLK) family may exert both 
growth-promoting and growth-inhibiting 
functions in cancer. KLKs are expressed in 
various tissues throughout the body and 
many of them are secreted into body fluids 
(Harvey et al. 2000; Shaw and Diamandis 
2007).  
The most abundant protease produced 
by the prostate and secreted into seminal 
fluid is PSA (or KLK3) (Shaw and 
Diamandis 2007). PSA is a serine protease 
with chymotrypsin-like enzymatic activity 
(Watt et al. 1986). The major biological 
function of PSA is degradation of the gel-
forming proteins, semenogelins, in seminal 
fluid, which leads to liquefaction of the 
seminal clot (Lilja 1985; Lilja et al. 1987). 
Several other functions, mostly based on 
proteolytic cleavage of different protein 
substrates, have been suggested for PSA 
(Borgono and Diamandis 2004; Lawrence et 
al. 2010). Some of these functions may also 
affect prostate cancer growth, but their 
biological significance is unknown.  
Once a tumor has grown to a size of a 
few millimetres in diameter, angiogenesis, 
the formation of new blood vessels, is 
essential for further growth (Hanahan and 
Folkman 1996; Folkman 2006). PSA exerts 
antiangiogenic activity, but the molecular 
mechanism and even the requirement for 
proteolytic activity has been unclear (Fortier 
et al. 1999; Fortier et al. 2003; Chadha et al. 
2011). Active PSA is present in high concen-
trations in the tumor microenvironment 
(Denmeade et al. 2001), which could 
facilitate inhibition of tumor angiogenesis. 
Several clinical studies have also shown that 
the overall effect of PSA in prostate cancer 
may be tumor-suppressive (Abrahamsson et 
al. 1988; Pretlow et al. 1991; Magklara et al. 
2000; Stege et al. 2000; Paju et al. 2007). 
The research presented in this thesis was 
performed to further characterize the 
antiangiogenic and proteolytic activities of 
PSA and to elucidate whether the proteolytic 
activity is needed for the antiangiogenic 
activity of PSA. The overall aim was to 
contribute to our understanding of the 
biological functions of PSA and ultimately to 
open new avenues for the treatment of 
prostate cancer. 
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REVIEW OF THE LITERATURE 
1. Prostate cancer 
Prostate cancer is the most common non-skin 
cancer in men and the second most common 
cause of cancer death in men in Finland; 
13.7% of all male cancer deaths in 2012 were 
caused by prostate cancer (Finnish Cancer 
Registry, www.syoparekisteri.fi, accessed 
April 2014). The incidence of prostate 
cancer in Finland was 81.2 cases per 100,000 
men, corresponding to 4604 new cancer 
cases, which was 30% of all detected non-
skin cancers in men in 2012.  
The general risk factors for prostate 
cancer are old age, ethnicity, family history, 
diet and other environmental factors (Wolk 
2005; Wilson et al. 2012). Genetic factors 
have been estimated to account for 40 - 60% 
of the prostate cancer risk (Lichtenstein et al. 
2000; Hjelmborg et al. 2014). Some genetic 
alterations in prostate cancer have been 
identified and these include mutations in 
tumor suppressor genes (such as TP53 and 
PTEN) and oncogenes (such as MYC) 
(Barbieri et al. 2013). Recurrent gene fusions 
of the androgen-regulated TMPRSS2 and the 
ETS-family of transcription factors have 
been found in about half of PSA-screened 
prostate cancers, the most common ETS-
gene fusion being TMPRSS2:ERG (Tomlins 
et al. 2005; Tomlins et al. 2009; Barbieri et 
al. 2013). There is contradictory evidence on 
how this gene fusion, which exposes the 
transcription factor to androgen regulation, 
affects prostate cancer growth (Tomlins et al. 
2009; Barbieri et al. 2013), but aberrant ERG 
expression together with the loss of PTEN 
have been found to promote prostate cancer 
progression (Carver et al. 2009). Genome-
wide association studies have also identified 
several single nucleotide polymorphisms 
(SNP), some of which are associated with 
prostate cancer risk (Eeles et al. 2014). 
The prostate gland is located below the 
urinary bladder and it surrounds the urethra. 
The prostate produces prostatic fluid, which 
is released during ejaculation into the 
prostatic urethra and mixed with 
spermatozoa and other glandular fluids, 
mainly seminal vesicle fluid, giving rise to 
seminal fluid. The prostate can be divided 
into three zones (central, peripheral and 
transition zones). Of these, the peripheral 
zone is the largest one and together with the 
central zone comprises about 95% of the 
prostatic glandular structure. Most prostate 
cancers (~ 70%) arise in the peripheral zone, 
but some arise in the transition zone which is 
the usual locus for benign prostatic 
hyperplasia (BPH) (McNeal et al. 1988; 
Crawford 2009). Prostate cancer is almost 
always an acinar adenocarcinoma, i.e., it 
arises from the glandular epithelium. There 
are several rare morphological variants, e.g., 
non-acinar neuroendocrine tumors and 
subtypes of adenocarcinoma which comprise 
5 - 10% of all prostate cancers (Fine 2012; 
Humphrey 2012).  
Compared to many other cancers 
prostate cancer typically grows slowly and it 
takes decades for the tumor to progress to 
clinical disease (Schmid et al. 1993; 
Stenman et al. 1999a). Prostate intra-
epithelial neoplasia (PIN), a putative 
precursor of prostate cancer, may arise in 
males aged only 20 - 30 years and develop 
into a malignant tumor decades later 
(Whittemore et al. 2005). According to an 
established view, the tumor grows rapidly 
until it reaches a size of ~ 1 mm3, i.e., the 
size when tumor needs its own vasculature 
for further growth (Hanahan and Folkman 
1996; Folkman 2006). This is followed by a 
slow growth phase of prostate cancer with 
doubling times of 2 to 3 years (Schmid et al. 
1993). The doubling time is assessed by the 
increase in the concentration of PSA in the 
serum, which correlates with the tumor 
volume (Stamey et al. 1987; Schmid et al. 
1993). The progression of most prostate 
cancers is relatively slow during the first 10 
to 15 years after diagnosis (Johansson et al. 
2004). 
Urination problems may be the first 
symptoms of prostate cancer, but often 
prostate cancer is symptomless at the time it 
is diagnosable on the basis of the 
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concentration of PSA in the blood. In men 
who develop prostate cancer, higher serum 
PSA concentrations occur even 25 to 35 
years before cancer is diagnosed by clinical 
symptoms, as compared to men who do not 
develop cancer (Whittemore et al. 2005; 
Lilja et al. 2011). PSA levels > 4 µg/L in the 
serum are generally considered to be 
elevated. The PSA level reflects the 
probability of cancer, i.e., a serum PSA of 
4 - 10 µg/L is associated with a 25% 
probability of prostate cancer (Catalona et al. 
1994; Thompson et al. 2004). However, PSA 
is not cancer specific, since serum PSA 
levels also increase in BPH and prostatitis 
(Stamey et al. 1987; Stenman et al. 2005), 
and consequently a sonographically guided 
prostate biopsy during digital rectal 
examination (DRE) is needed for definite 
diagnosis. In advanced prostate cancer, bone 
metastases that can be detected by 
radionuclide imaging are common. 
Screening of prostate cancer is based on 
assessment of serum PSA and needle biopsy. 
PSA screening has increased dramatically 
during the recent decades. As a result of 
screening, most prostate cancers are 
currently detected at an early stage and have 
a favorable prognosis. This has led to an 
increase in the incidence of prostate cancer, 
since opportunistic screening of healthy men 
identifies cancers that may never have 
surfaced clinically during the lifetime of the 
person nor would have threatened his life 
(Stenman et al. 2005) (see also section 4.7. 
Clinical use of PSA).  
The tumor-node-metastasis (TNM) 
staging system is used for determination of 
the progression of prostate cancer. The TNM 
stage, together with the Gleason score 
determined from microscopic examination 
of tumor biopsies, are used when the therapy 
and prognosis of the prostate cancer patient 
are evaluated. There are four clinical stages 
of prostate cancer according to the TNM 
system: stage I and II refer to local, III to 
locally advanced (tumor has spread through 
the prostatic capsule) and stage IV to 
metastatic cancer. The Gleason grading 
system is used to evaluate the aggressiveness 
of the tumor. It comprises grades from 1 - 5 
where a higher grade indicates a poorly 
differentiated, more aggressive tumor and a 
worse prognosis. The Gleason score is the 
sum of the two most prevalent grades. The 
patient’s prognosis is also associated with 
serum PSA and especially the fraction of free 
PSA (Stenman et al. 2005). Genetic markers 
may also be useful aids for prostate cancer 
screening, prognosis and prediction of 
response to treatment, but they have not been 
thoroughly validated for such use 
(Choudhury et al. 2012). 
Radical prostatectomy and radiation 
therapy are often used to treat TNM stage I 
and II tumors, while radiation, hormonal 
therapy and chemotherapy are used for 
treatment of stage III and IV tumors. 
Androgen-dependent prostate cancer can be 
treated with hormonal therapy carried out by 
castration or by administration of antiandro-
gens that reduce testosterone levels. During 
tumor progression, the cancer often develops 
resistance to this treatment. Several drugs 
have been developed to treat castration-
resistant prostate cancer, but these are not 
curative and their effect on survival is 
modest, months rather than years (Tammela 
2012). Treatment of prostate cancer depends 
on the size and spread of the tumor, but also 
on the age of the patient and his concurrent 
diseases. Especially for elderly patients with 
local low-risk tumors, active surveillance 
(monitoring serum PSA levels, DRE and 
regular prostate biopsies) is often the best 
option since the cancer usually progresses 
slowly and the patient may ultimately die 
from other conditions than his prostate 
cancer.  Naturally, treatment will be started 
if tumor shows signs of rapid growth or of 
spreading (Welty et al. 2014).  
 
2. Proteases 
Degradome, the complete set of proteases 
(also called peptidases, proteinases or 
proteolytic enzymes) comprises ~ 2% of all 
proteins encoded by the human genome 
(Lopez-Otin and Overall 2002; Barrett et al. 
2004; Puente et al. 2005; Turk et al. 2012). 
Proteases are enzymes that catalyze protein 
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cleavage by hydrolyzing peptide bonds in a 
process termed proteolysis, which is an 
irreversible reaction. Proteases cleave their 
protein or peptide substrates either from the 
carboxy or amino terminus (exopeptidases), 
or in the middle of the polypeptide chain 
(endopeptidases) (Barrett et al. 2004). 
Proteases regulate the localization and 
activity of other proteins, are involved in 
protein-protein interactions, generate new 
bioactive molecules and contribute to 
signaling pathways in multiple biological 
processes (Lopez-Otin and Bond 2008). 
They are important regulators of biological 
processes such as angiogenesis, apoptosis, 
blood coagulation, digestion, reproduction, 
embryonic development, neurogenesis, 
wound healing, inflammation and immunity, 
and are active both in health and disease. 
These proteins exhibit a huge diversity both 
in function and structure. They are mainly 
localized either extracellularly or intracellu-
larly, but some proteases are also bound to 
membranes (Turk et al. 2012).  
 
2.1 Classification 
Mammalian proteases have been categorized 
according to their catalytic mechanism of 
action into aspartic, cysteine, metallo-, serine 
and threonine proteases. Proteases are 
further grouped on the basis of their 
homology into clans and families, a clan 
containing one or more families (Rawlings 
and Barrett 1993). The proteases of the same 
family have significant similarity of amino 
acid sequence, at least in the catalytically 
active region, and families are grouped into 
clans based on their similar three-
dimensional structures, which implies a 
common evolutionary origin (Rawlings and 
Barrett 1993; Barrett et al. 2004). 
The Mammalian Degradome Database 
(http://degradome.uniovi.es/dindex.html, ac-
cessed April 2014; Quesada et al. 2009) 
currently comprises 584 human proteases, 21 
of which are aspartic proteases, 161 cysteine, 
191 metallo-, 184 serine and 27 threonine 
proteases. A similar number of genes were 
recorded as encoding proteases or protease 
homologues in the human genome already a 
decade ago (Puente et al. 2003). However, 
these numbers are not definitive and they 
may change as new proteases are discovered. 
The MEROPS database of proteolytic 
enzymes lists 1023 known and putative 
human peptidases (MEROPS Release 9.11, 
http://merops.sanger.ac.uk, accessed Sep-
tember 2014; Rawlings et al. 2012). The 
number of putative peptidases is constantly 
growing, as peptidase homologues have been 
sequenced faster than they can be 
characterized (Rawlings et al. 2012). 
 
2.2 Specificity and catalytic mechanism 
The substrate specificity of proteases varies 
considerably. Some proteases are strictly 
specific for a certain peptide bond in one 
protein, while others target non-specifically 
several substrates (Lopez-Otin and Bond 
2008). The substrate specificity is deter-
mined by the structure of the active site of 
the proteolytic enzyme, although more 
distinct areas may also be involved. The 
active site is formed by amino acid residues 
that may be located far from each other in the 
protein sequence but which are close to each 
other in the three-dimensional conformation 
of the protease. When in close proximity, 
these amino acids form a catalytic pocket or 
a cleft where the enzymatic reaction occurs. 
The active site residues participate directly in 
the catalytic reaction.  
The catalytic mechanism of aspartic and 
metalloproteases for hydrolysis of peptide 
bonds exploits an activated water molecule 
as a nucleophile, while cysteine, serine and 
threonine proteases exploit oxygen or sulfur 
atoms of the catalytic amino acid (Cys, Ser 
or Thr, respectively) located in their active 
site (Puente et al. 2003; Barrett et al. 2004; 
Lopez-Otin and Bond 2008). The aspartic 
proteases contain two highly conserved 
aspartates in the active site, the other being 
responsible for the activation of the water 
molecule, while in the metalloproteases, a 
metal ion (usually Zn2+) activates the water 
molecule (Barrett et al. 2004). In the cysteine 
proteases, the catalytic reaction is based on a 
nucleophilic attack of a thiol (or sulfhydryl) 
group of the catalytic cysteine and in the 
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serine and threonine proteases of the 
hydroxyl group of the catalytic serine or 
threonine.  
The catalytic site of the protease is 
flanked by specific binding sites or subsites 
which interact with amino acid side chains of 
the substrate residues. While the amino acid 
residues in substrates are located consecu-
tively in the primary structure (sequence), 
the subsites of the protease are close to each 
other in the three-dimensional structure, but 
not necessary in the primary structure, and 
each subsite is generally formed by several 
amino acids.  The amino acid residues of the 
substrate which interact with the subsites in 
the protease are numbered starting from the 
scissile bond of the substrate, i.e., the peptide 
bond that is hydrolyzed, in both directions: 
P1-Pn towards the N-terminus (non-primed 
side) and P1’-Pn’ towards the C-terminus of 
the substrate (primed side). P1 is the amino 
acid after which the enzyme cleaves the 
substrate. The corresponding subsites of the 
protease are numbered accordingly: S1-Sn 
and S1’-Sn’ (Berger and Schechter 1970; 
Barrett et al. 2004; Turk 2006) (Figure 1).  
Serine proteases form the functionally 
most diverse group of proteases, comprising 
about 30% of all proteases (Puente et al. 
2003; Southan 2001; Di Cera 2009). There 
are 9 clans of serine proteases with about 50 
families, family S1 being the largest one 
(Barrett et al. 2004). The serine proteases of 
this family include, among others, the diges-
tive enzymes trypsin and chymotrypsin, as 
well as the kallikrein-related peptidases 
(KLK) (Yousef and Diamandis 2001; 
Hedstrom 2002). Trypsin cleaves polypep-
tide chains after positively charged residues 
(Arg or Lys at the P1 position), while 
chymotrypsin prefers to act on large 
hydrophobic residues (Phe, Trp or Tyr at the 
P1 position) (Di Cera 2009).  
 
 
 
 
 
 
 
Figure 1. Schematic representation of the interaction of a protease with its protein substrate (adapted from Turk 
2006). At the active site, specific subsites on the surface of a protease interact with amino acid side chains of 
the substrate residues. The subsites of the protease are numbered S1-Sn towards the N-terminus of the 
substrate (non-primed sites) and S1’-Sn’ towards the C-terminus of the substrate (primed sites). 
Correspondingly, the amino acid residues of the substrate are numbered P1-Pn and P1’-Pn’ starting from the 
scissile bond between P1 and P1’ which is cleaved by the protease.  
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The active site of serine proteases is typically 
formed by a catalytic triad of three amino 
acid residues. For example in chymotrypsin, 
the catalytic triad is formed by His57, 
Asp102 and Ser195, the nucleophilic serine 
being the catalytically active residue, and the 
reaction is stabilized by the peptide 
backbone NH-groups of residues Gly193 
and Ser195, which form an oxyanion hole 
(Barrett et al. 2004). The interactions 
between protease subsites and substrate 
residues align the substrate to the catalytic 
triad and determine the specificity of the 
protease, the S1-P1 interaction being the 
primary determinant of specificity (Barrett et 
al. 2004). In chymotrypsin-like serine 
proteases, the S1 specificity pocket is formed 
by residues 189-192, 214-216 and 224-228, 
and the specificity is usually determined by 
residues 189, 216 and 226 (chymotrypsin 
numbering) (Hedstrom 2002).  
 
2.3 Regulation of proteolytic activity 
Proteolytic enzymes must be strictly 
regulated, since they catalyze irreversible 
peptide bond cleavages. Regulation of their 
activity takes place at several levels, e.g., 
during gene expression, through post-
translational modifications and through 
activation and inhibition. In addition to their 
catalytic domains, proteases have various 
other domains or modules, which increase 
the complexity of their function (Lopez-Otin 
and Bond 2008; Turk et al. 2012). 
Different proteases are expressed in 
different tissues and cell types. Some are 
ubiquitous and others are very specific for a 
certain tissue (Turk et al. 2012). Some 
proteases are expressed at a constant rate, 
while others are expressed only under 
specific conditions, e.g., during develop-
ment. Alternative mRNA splicing increases 
the functional diversity of the proteases and 
post-translational modifications, such as 
glycosylation, phosphorylation and addition 
of co-factors, provide further means to 
control the protease activity (Lopez-Otin and 
Bond 2008).  
Many proteases are synthesized as 
inactive preproenzymes, which have an N-
terminal signal sequence that directs the 
protease for the secretion pathway, and a 
propeptide sequence, the removal of which 
generates the active enzyme. The inactive 
precursors with the propeptide sequence are 
called zymogens or proenzymes. The sizes 
of the propeptide sequences can vary 
considerably. Cleavage of the propeptide can 
be mediated by the protease itself 
(autoactivation) or by other proteases. In a 
zymogen, the active site is either fully 
formed, but sterically blocked by a propep-
tide, or the active site is only formed by a 
conformational change resulting from the 
propeptide cleavage. The latter activation 
mechanism is characteristic for chymotryp-
sin-like serine proteases (Khan et al. 1999; 
Hedstrom 2002; Turk et al. 2012). Many 
proteases act in proteolytic cascades, where 
one protease activates another which further 
catalyzes activation of a protease down-
stream the cascade and this forms a complex 
network with amplification of the proteolytic 
action (Turk et al. 2012). Well-characterized 
proteolytic cascades are the coagulation 
protease cascade in blood coagulation 
(Davie et al. 1991) and the caspase cascade 
in apoptosis (Li et al. 1997; Fuentes-Prior 
and Salvesen 2004).  
Protease activity is regulated by several 
protease inhibitors. Serine protease 
inhibitors, serpins, mostly inhibit trypsin- 
and chymotrypsin-like serine proteases 
(Silverman et al. 2001; Law et al. 2006), 
while tissue inhibitors of metalloproteinases 
(TIMP) are the main inhibitors of the 
metalloproteases (Murphy 2011). There are 
much less protease inhibitors than proteases, 
since most inhibitors can inhibit several 
proteases, usually of the same family, but 
some, e.g., α2-macroglobulin, inhibits vari-
ous classes of proteases (Turk et al. 2012; 
Rawlings et al. 2012).  
The mechanism of protease inhibition 
varies: there are reversible and irreversible 
inhibitors. Reversible inhibitors bind the 
target protease with non-covalent interac-
tions. Some of them bind directly to the 
active site of the protease and compete with 
the substrate for binding (competitive 
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inhibition), while some bind to the substrate-
protease complex (uncompetitive inhibi-
tion). Allosteric inhibitors bind distant from 
the active site and change the protein confor-
mation making the active site inaccessible 
for the substrate, while non-competitive 
inhibitors reduce the enzymatic activity of 
the protease but do not affect the binding of 
the substrate (Bode and Huber 2000). 
Irreversible inhibition involves chemical 
reactions and covalent modifications. 
Irreversible inhibitors, such as the serpins, 
form a covalent complex with the protease in 
a multistep process and subsequently serpin 
undergoes massive conformational changes 
that inhibit both the serpin and the protease 
(Ye and Goldsmith 2001; Turk et al. 2012). 
The activity of several serine proteases 
is also regulated reversibly by metal ions, 
and Zn2+ is the most common metal ion in 
this context. For example, several KLKs are 
inhibited by micromolar concentrations of 
Zn2+ (Malm et al. 2000; Goettig et al. 2010; 
Swedberg et al. 2010). 
 
2.4 Proteases in cancer  
Increased proteolytic activity is closely 
associated with cancer progression. 
Proteases are involved in tumor invasion and 
metastasis, as proteolytic degradation of the 
ECM is a requirement for cancer invasion 
into surrounding tissues and for metastasis 
(Hanahan and Weinberg 2000; Hanahan and 
Weinberg 2011). In addition to cancer cells, 
many other cells of the tumor microenviron-
ment produce proteases, which are involved 
in various stages of cancer progression 
(Räsänen and Vaheri 2010).   
As the complexity of protease action has 
been unfolding, it has become evident that all 
proteolytic functions may not lead to in-
creased cancer growth. Individual proteases 
may have multiple functions, some of which 
may promote tumor growth, while others 
may be tumor-suppressive (Lopez-Otin and 
Matrisian 2007; Drag and Salvesen 2010; 
Mason and Joyce 2011). For example, matrix 
metalloproteinases (MMP) facilitate cell 
invasion, but may also inhibit cancer cell 
growth by inducing apoptosis and by 
producing antiangiogenic fragments from 
plasminogen and collagen type IV 
(Kessenbrock et al. 2010). Proteases can also 
activate protease activated receptors (PAR) 
and participate in the regulation of other 
signaling molecules, such as kinases and 
growth factors, which are essential for 
cancer development (Lopez-Otin and Hunter 
2010; Ramachandran et al. 2012).  
Proteases are also of considerable 
interest for the pharmaceutical industry, as 
they are potential biomarkers and targets for 
drug action (Turk 2006). It has been 
estimated that 5 - 10% of the potential 
targets for drug development are proteases 
(Drag and Salvesen 2010). The general 
strategy for protease-targeting drug 
development is to find a specific inhibitor for 
a protease; however, the number of new 
approved protease inhibitors has been 
limited. Poor specificity is often a problem 
with the use of protease inhibitors. Such 
drugs may inhibit other similar proteases in 
addition to their target, and thus interfere 
inappropriately with protease networks that 
are essential for normal physiology. Thus, 
when broad-range MMP-inhibitors were 
evaluated for cancer treatment, many clinical 
trials failed because of serious side effects 
and poor efficacy demonstrating the 
diversity and complexity of the MMP 
functions in cancer (Drag and Salvesen 
2010; Dufour and Overall 2013). 
The functions of proteases in prostate 
cancer are not well understood. MMPs 
regulate many cancer-related functions in the 
tumor microenvironment, and they are also 
involved in prostate cancer development, 
metastasis and angiogenesis (Kessenbrock et 
al. 2010; Littlepage et al. 2010). Especially 
MMP-2 has been shown to be essential for 
prostate cancer progression, since MMP-2 
deficiency in transgenic mice decreases 
tumor growth, metastasis and blood vessel 
density, and increases survival (Littlepage et 
al. 2010). Other proteases, e.g., the members 
of a disintegrin and metalloproteinase/with 
thrombospondin motifs (ADAM/TS) prote-
ase family, urokinase-type plasminogen 
activator/ receptor (uPA/uPAR) system and 
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the membrane-associated type II trans-
membrane serine proteases, such as hepsin 
and matriptase, are all involved in prostate 
cancer progression and metastasis (reviewed 
in Rocks et al. 2008; Dass et al. 2008; Bugge 
et al. 2009). The KLKs, a protease family 
with highly prostate-specific members, e.g., 
PSA (KLK3) and KLK2, are closely associ-
ated with prostate cancer development. 
 
3. Kallikrein-related peptidases 
The name kallikrein is derived from the 
Greek word for pancreas, “kallikreas”, as the 
first kallikrein discovered in the 1930s, 
tissue kallikrein (KLK1), occurred at high 
concentration in the pancreas (reviewed in 
Bhoola et al. 1992). During the 1970s and 
1980s, two other tissue kallikrein family 
members were identified in seminal fluid, 
human glandular kallikrein-1 (also known as 
hK2 or KLK2) and prostate-specific antigen 
(PSA or KLK3) (Lundwall and Lilja 1987; 
Schedlich et al. 1987) (for the discovery of 
PSA see also section 4.7. Clinical use of 
PSA). These three kallikreins are considered 
to be the classical tissue kallikreins and share 
a unique kallikrein loop that has been 
proposed to regulate their substrate 
specificity (Yousef and Diamandis 2001; 
Lawrence et al. 2010; Thorek et al. 2013).  
Around the year 2000, several other 
kallikrein genes encoding for serine 
proteases were identified in the same 
chromosomal location as the classical tissue 
kallikreins (Gan et al. 2000; Harvey et al. 
2000; Yousef et al. 2000). A comprehensive 
nomenclature for the extended tissue 
kallikrein family with 15 members was 
established in 2006. The kallikreins, with the 
exception of tissue kallikrein (KLK1), were 
renamed kallikrein-related peptidases 
(KLK2-15) (Lundwall et al. 2006). Plasma 
kallikrein (KLKB1) is another serine 
protease with similar function as KLK1, 
cleaving kininogens to release kinin 
peptides, but it differs significantly from the 
tissue kallikreins in its gene and protein 
structure, chromosomal location as well as 
substrate specificity, and thus, it does not 
belong to the tissue kallikrein family (Yousef 
and Diamandis 2001).  
The KLKs form the largest known 
contiguous protease gene cluster with 15 
functional genes and several pseudogenes 
located in human chromosomal region 
19q13.3-13.4 (Gan et al. 2000; Harvey et al. 
2000; Yousef et al. 2000; Yousef and 
Diamandis 2001; Puente et al. 2003; 
Lawrence et al. 2010) (Figure 2). 
Transcription of the KLKs occurs mostly 
from telomere to centromere except for 
KLK2 and KLK3, which are transcribed in 
the opposite direction. All KLK genes 
encode serine proteases with a conserved 
catalytic triad. They comprise five protein-
encoding exons of similar size separated by 
four introns, which are more variable in size 
and sequence (Yousef and Diamandis 2001; 
Lawrence et al. 2010). 
Human KLK2 and KLK3 share 67% and 
62% similarity, respectively, in their amino 
acid sequence with KLK1, while for KLK4-
15 the sequence similarity with KLK1 is 
27 - 39% (Harvey et al. 2000). The highest 
sequence similarity (78%) between the 
members of the human KLK family is the 
one between the mature forms of KLK2 and 
KLK3 (without propeptide) (Schedlich et al. 
1987). A progenitor gene of KLK2 evolved 
probably by duplication of KLK1, while 
KLK3 evolved later during the course of 
evolution by duplication of KLK2 (Lundwall 
et al. 2006; Pavlopoulou et al. 2010; 
Lundwall 2013). Thus, KLK3 is present only 
in higher primates, and there are no 
orthologues of KLK2 and KLK3 in mouse or 
rat genomes, nor of KLK3 in dog (Elliott et 
al. 2006; Pavlopoulou et al. 2010; Marques 
et al. 2012; Lundwall 2013). The major 
substrates of KLK3 in the seminal fluid, 
semenogelins I and II, are also unique to 
primates (Jonsson et al. 2006). 
The KLKs belong to the S1A family of 
the PA clan of serine proteases and are 
synthesized as proteolytically inactive 
preproenzymes which must be processed 
before they become enzymatically active 
(Lawrence et al. 2010).  A  16  to  33  amino  
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Figure 2. Chromosomal location, gene and protein structure of PSA (KLK3) (data extracted from Ensembl 
database release 75). The chromosomal region 19q13.3-13.4 contains the KLK gene cluster (KLK1-15). KLK2 and 
KLK3 are located in the forward strand and the other KLKs in the reverse strand, transcription direction is shown 
by the arrows. The protein-encoding exons of KLK3 gene are numbered (1-5) and the four introns are shown in 
dark grey. The proximal androgen response elements (ARE I and II) are shown upstream of the transcription start 
site (arrow). PSA is translated as a preproenzyme containing a signal sequence (pre) for secretion and a pro-
sequence for activation. The pre- and pro-sequences are removed during the secretion and activation processes, 
respectively, to generate the mature protein. The amino acids of the catalytic triad (His57, Asp102 and Ser195), 
the glycosylation site (Asn45), and kallikrein loop are shown in the protein structure. 
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acid long N-terminal signal sequence (pre) 
directs the newly synthesized KLKs to the 
endoplasmic reticulum and the secretory 
pathway. Cleavage of a 3 to 37 amino acid 
long propeptide (pro) induces a conforma-
tional change in the protein making the 
KLKs enzymatically active, mature prote-
ases. 
Activation typically takes place after 
arginine or lysine residues, indicating that 
the KLKs are activated by trypsin-like 
peptidases, such as other KLKs (Yoon et al. 
2007). The regulation of KLK activation is 
thought to occur in a complex network of 
proteolytic cascades, where some KLKs, 
after autoactivation, further activate other 
KLKs in a complex cascade-like manner 
called the “KLK activome” (Yoon et al. 
2007; Sotiropoulou et al. 2009). However, 
this may represent a simplified view, as also 
other proteases that are able to activate 
KLKs, such as trypsin, are expressed in the 
same tissues as KLKs (Paju et al. 2000). 
Enzymatically active KLKs participate 
in various proteolytic events. Their 
proteolytic activity is characterized by the 
catalytic triad of the active site: one 
catalytically active serine residue is situated 
in an internal pocket with aspartate and 
histidine residues at a close distance in the 
three-dimensional structure (Di Cera 2009). 
The substrate specificity of the KLKs is 
dependent on amino acid residue 189 
(chymotrypsin numbering), which is located 
in the bottom of the specificity pocket of the 
enzyme and allows them to cleave after 
specific residue in the substrate. For KLK1, 
2, 4, 5, 6 and 10 - 14 residue 189 is aspartate, 
while in KLK3 it is serine, in KLK7 
asparagine,
 
in KLK9 glycine
 
and in KLK15 
glutamate (Yousef and Diamandis 2001; 
Lawrence et al. 2010). Most KLKs have 
trypsin-like substrate specificity with a 
preferred P1 amino acid residue being 
arginine or lysine (Di Cera 2009; Thorek et 
al. 2013). In contrast to this, KLK3 and 
KLK7 have exclusively chymotrypsin-like 
specificity, and they cleave typically after 
tyrosine or phenylalanine, while KLK1, 10 
and 11 have both trypsin and chymotrypsin 
specificity (Di Cera 2009; LeBeau and Craik 
2012; Rawlings et al. 2012; Thorek et al. 
2013). 
The KLKs are expressed in different 
tissues throughout the body and many are 
secreted into body fluids (Harvey et al. 2000; 
Shaw and Diamandis 2007). The KLKs are 
divided into three groups according to their 
expression pattern in the different tissues: 
those that are highly restricted to one specific 
tissue (KLK2 and KLK3 to prostate), those 
restricted to 2 - 4 tissues (KLK5-8 and 13) 
and those expressed widely in different 
tissues (KLK1, 4, 9-12, 14 and 15) (Shaw 
and Diamandis 2007) (Figure 3). Several 
KLKs are expressed in the prostate, while 
KLK2 and KLK3 are by far the most 
abundant ones (Shaw and Diamandis 2007). 
At the mRNA level, all 15 KLKs have been 
detected in prostate tissue at low levels, but 
the highest expression has been recorded for 
KLK1, 2, 3 and 10 in one study (Shaw and 
Diamandis 2007) and for KLK2, 3 and 4 in 
another study (Harvey et al. 2000). At the 
protein level, the highest protein 
concentrations in prostate tissue extracts 
have been measured with specific enzyme-
linked immunosorbent assays (ELISA) for 
KLK2, 3 and 11 (Shaw and Diamandis 
2007). These three are also the main KLKs 
in seminal plasma, where KLK3 is the most 
abundant seminal fluid protein of prostatic 
origin (Shaw and Diamandis 2007; Veveris-
Lowe et al. 2007). 
Various physiological roles have been 
suggested for the KLKs, but much about 
their function is still unknown. KLK1 
releases kinins by cleaving low-molecular 
weight kininogen. It is involved in the 
regulation of blood pressure, smooth muscle 
contraction, vascular permeability, inflam-
mation and pain (Bhoola et al. 1992; Moreau 
et al. 2005). KLK2, 3, 5 and 14 degrade 
semenogelins I and II in the seminal fluid, 
which promotes semen liquefaction and thus 
improves the motility of the spermatozoa 
(Lilja 1985; Deperthes et al. 1996; Michael 
et al. 2006; Emami et al. 2008). KLK4 is 
involved in amelogenesis (the formation of 
tooth   enamel)    by    processing    enamelin
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Figure 3. Relative mRNA expression levels of KLK3 (PSA) in different tissues. The data from IST Online database 
containing gene expression data of over 15,000 samples shows that the expression of KLK3 is highly restricted 
to the prostate (http://www.genesapiens.org, accessed September 2014; Kilpinen et al. 2008). 
 
 
(Yamakoshi et al. 2006), KLK5, 7 and 14 
play a role in skin desquamation (Caubet et 
al. 2004; Brattsand et al. 2005) and KLK6 is 
associated with pathological states of the 
brain and ovarian cancer (Iwata et al. 2003; 
Magklara et al. 2003; Shan et al. 2007).  
In addition to the suggested physiologi-
cal functions, most KLKs have a number of 
functions related to cancer (reviewed in 
Borgono and Diamandis 2004; Sotiropoulou 
et al. 2009; Lawrence et al. 2010). The KLKs 
exert tumor growth-promoting functions and 
are involved in the degradation and 
remodeling of ECM, invasion and metastasis 
and epithelial to mesenchymal transition 
(EMT). KLKs can release insulin-like 
growth factors (IGF) from IGF-binding 
proteins and KLK2, 4, 5, 6 and 14 participate 
in the regulation of cell signaling by 
activation of PARs (Oikonomopoulou et al. 
2006; Mize et al. 2008; Ramsay et al. 2008). 
KLKs also have tumor-suppressive 
functions, such as release of angiostatin-like 
fragments and activation of transforming 
growth factor-β (TGF-β), and thus, they may 
play dual roles in cancer. However, the 
activation of TGF-β may also lead to tumor 
growth-promoting functions. 
Several KLKs are potential biomarkers 
for different cancers. PSA (KLK3) is the best 
screening marker for prostate cancer, but in 
addition KLK2 and KLK11 could also be 
useful biomarkers for prostate cancer, while 
KLK6 might be suitable as a marker for 
ovarian cancer (Paliouras et al. 2007; Emami 
and Diamandis 2008).  
 
4. Prostate-specific antigen  
4.1 Gene structure 
Like the other KLK genes, KLK3 consists of 
five protein-encoding exons that are 
separated by four introns (Figure 2). 
According to the Ensembl database, there are 
currently 15 known alternative splicing 
variants for KLK3 (eight of which are 
protein-coding) (Ensembl release 75; Flicek 
et al. 2014). Some of these splicing variants 
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are expressed differently in cancer than in 
normal tissue or in BPH (Tanaka et al. 2000; 
David et al. 2002; Heuze-Vourc'h et al. 2003; 
Pampalakis et al. 2008; Whitbread et al. 
2010). However, the relevance of the 
splicing variants regarding normal prostate 
physiology or cancer is unclear, as they are 
neither enzymatically active nor found in the 
seminal fluid (Heuze-Vourc'h et al. 2003; 
Whitbread et al. 2010). Several SNPs have 
also been identified within the KLK3 gene 
region. Some of these SNPs alter KLK3 gene 
expression and affect serum PSA levels, and 
may in this way be associated with prostate 
cancer or they may at least increase the 
chance of being diagnosed with prostate 
cancer by elevated PSA (Ahn et al. 2008; 
Eeles et al. 2014). 
The gene expression of PSA is hormo-
nally regulated by androgens that bind to 
androgen response elements (ARE) in the 
promoter region of KLK3 and activate the 
androgen receptor (AR). Two AREs are 
present within the proximal promoter of 
KLK3 at positions 170 bp (ARE I) and 
394 bp (ARE II) upstream of the 
transcription start site (Riegman et al. 1991; 
Cleutjens et al. 1996) (Figure 2). Several 
other AREs with lower affinity have been 
identified inside of an enhancer element 
located between -5824 and -3738 bp (Schuur 
et al. 1996; Huang et al. 1999).  
 
4.2 Protein structure 
PSA is synthesized as a 261-amino acid long 
preproprotein containing a 17-amino acid 
signal peptide (pre) and a 7-amino acid 
propeptide (Lundwall and Lilja 1987; 
Yousef and Diamandis 2001) (Figure 2). The 
signal sequence directs the protein to the 
secretory pathway and is removed prior to 
secretion into the prostatic ducts. Inactive 
proenzyme (proPSA) is activated in vitro by 
the cleavage of the propeptide by several 
trypsin-like proteases, e.g., KLK2, KLK5 
and trypsin (Kumar et al. 1997; Lövgren et 
al. 1997; Takayama et al. 1997; Paju et al. 
2000; Michael et al. 2006). Active PSA is a 
28.4 kDa single-chain glycoprotein of 237 
amino acids containing five disulfide bridges 
and 8.3% carbohydrate in the form of one N-
linked glycan on Asn45 (Watt et al. 1986; 
Lundwall and Lilja 1987; Belanger et al. 
1995; Menez et al. 2008). The protein 
structure of human PSA has been determined 
by X-ray crystallography with an activity-
stimulating antibody and a substrate (Menez 
et al. 2008).  
 
4.3 Expression 
PSA is highly expressed in prostatic tissue 
(Figure 3) by the luminal epithelial cells as 
shown by immunohistochemistry (Ben 
Jemaa et al. 2010; Lawrence et al. 2010). In 
prostate tissue extracts there is around 10 mg 
of PSA per gram of tissue (Shaw and 
Diamandis 2007), and the concentration of 
PSA in seminal fluid is 0.5 - 3 g/L (Wang et 
al. 1998; Lövgren et al. 1999a; Savblom et 
al. 2005). PSA is present in low concentra-
tions in other biological fluids, like breast 
milk, breast cancer cytosol, amniotic fluid, 
saliva and urine (ranging from 0.1 to 
100 µg/L), as well as in other tissue extracts, 
e.g.,  ureter, testis, stomach, heart, muscles 
and spleen (median between 0.5 and 2 µg/g 
of tissue) (Lövgren et al. 1999a; Shaw and 
Diamandis 2007). Interestingly, PSA con-
centrations around 2 µM (~ 60 mg/L) have 
been measured in the extracellular fluid in 
normal prostatic tissue and in the prostate 
cancer tissue, with 80 - 90% of PSA being 
enzymatically active (Denmeade et al. 
2001).  
The PSA concentrations in blood are 
physiologically low; the median level is 
0.6 µg/L, which is one millionth of the level 
in seminal fluid (Savblom et al. 2005). In 
prostate cancer, serum concentrations of 
PSA increase, despite decreasing levels of 
PSA in prostatic tissue as the cancer 
progresses (Abrahamsson et al. 1988; Paju et 
al. 2007). The increase in serum PSA is 
explained by disruption of the prostate tissue 
architecture by the tumor: the basal 
membrane structure becomes destroyed and 
epithelial cell polarity is lost. Thus, the 
secretory pathway to the prostatic ducts 
becomes disrupted with increased leakage of 
PSA into the extracellular space (Stenman 
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1997; Lilja et al. 2008). The released PSA 
will then diffuse into the circulation 
(Stenman 1997). 
 
4.4 Complexed and nicked forms of PSA 
In the circulation, enzymatically active PSA 
is rapidly inactivated by the formation of 
complexes with protease inhibitors such as 
α1-antichymotrypsin (ACT) (Lilja et al. 
1991; Stenman et al. 1991), α1-protease 
inhibitor (API) (Zhang et al. 1997) and α2-
macroglobulin (A2M) (Zhang et al. 2000). 
The major complexed form of PSA in the 
circulating blood is PSA-ACT, while PSA-
API represents 1 - 10% and PSA-A2M 
2 - 40% of the total PSA in plasma (Zhang et 
al. 1997; Zhang et al. 2000). About 5 - 40% 
of the PSA in the circulation is free and most 
of this free PSA (fPSA) is enzymatically 
inactive. Inactive fPSA consists of intact and 
truncated forms of proPSA and different 
internally cleaved (“nicked”) or truncated 
forms of mature PSA (Mikolajczyk et al. 
1997a; Noldus et al. 1997; Charrier et al. 
1999; Mikolajczyk et al. 2000). Different 
forms of proPSA, which include the full-
length 7-amino acid propeptide (-7)proPSA 
as well as several truncated forms, i.e., (-5), 
(-4), (-2) and (-1)proPSA, comprise 
25 - 50% of the fPSA (Mikolajczyk et al. 
1997a; Peter et al. 2001; Niemelä et al. 
2002). A small fraction (1 - 10%) of fPSA in 
plasma is enzymatically active (Niemelä et 
al. 2002; Wu et al. 2004b; Zhu et al. 2009).  
In seminal fluid PSA is present mainly 
in the free form, but less than 5% is bound to 
protein C inhibitor (Espana et al. 1991; 
Christensson and Lilja 1994). Thus, most of 
the PSA is enzymatically active, while about 
30% occurs in inactive, internally cleaved 
(“nicked”) forms (Christensson et al. 1990; 
Zhang et al. 1995). Two differentially 
glycosylated active isoforms, PSA-A and 
PSA-B, and three internally cleaved forms, 
PSA-C, PSA-D and PSA-E, can be isolated 
from seminal fluid by anion-exchange 
chromatography (Zhang et al. 1995). The 
activity of PSA in the seminal fluid is 
regulated by Zn2+, which is an inhibitor of 
PSA activity (Malm et al. 2000) (see also 
4.6. Biological function of PSA).  
 
4.5 Proteolytic activity and specificity 
Several trypsin-like proteases, including 
trypsin, KLK2, 4 and 5, can activate proPSA 
by cleavage of the propeptide sequence (Paju 
et al. 2000; Michael et al. 2006; Lövgren et 
al. 1997; Kumar et al. 1997; Takayama et al. 
1997; Takayama et al. 2001). Active PSA 
exerts chymotrypsin-like enzymatic activity 
(Watt et al. 1986; Akiyama et al. 1987). 
However, PSA is considered to be a weak 
protease in comparison to chymotrypsin 
(Watt et al. 1986; Denmeade et al. 1997; 
Coombs et al. 1998) and its substrate 
specificity is also more restricted than that of 
chymotrypsin, apparently because the 
kallikrein loop restrains the access of 
substrates to the active site (Debela et al. 
2006; Menez et al. 2008).  
The specificity pocket with Ser189 at 
the bottom determines the specificity of 
PSA. In addition to Ser189, the residues 
Thr190, Thr213 and Ser226 are involved in 
forming a pocket that is polar at the bottom 
and hydrophobic on the sides, suggesting 
that PSA prefers substrates with hydropho-
bic side chains, such as tyrosine, at the P1 
position (Villoutreix et al. 1994; Coombs et 
al. 1998; LeBeau et al. 2009). Other 
surrounding residues are also likely to 
contribute to the substrate specificity of PSA 
(LeBeau et al. 2010). PSA typically cleaves 
its substrates after tyrosine and glutamine, 
but other residues, such as leucine or 
phenylalanine, have also been reported to 
occur in the P1 position of the cleavage site 
(Debela et al. 2006; LeBeau and Craik 2012; 
Rawlings et al. 2012) (Figure 4). This is 
somewhat different from the specificity of 
chymotrypsin, which preferentially cleaves 
after phenylalanine, tryptophan or tyrosine 
(Di Cera 2009).  
Various cleavage sites have been 
identified for PSA in different substrates, 
e.g., PSA cleaves semenogelins I and II 
predominantly after tyrosine and glutamine 
residues, respectively, while serine was 
observed  most  often  at  the  P1’ position  in
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Figure 4. The cleavage site specificity of PSA. The cleavage site sequence logo generated by WebLogo (version 
2.8.2, http://weblogo.berkeley.edu/) is based on 83 cleavages of peptide and protein substrates that are listed 
in the MEROPS database for PSA (Crooks et al. 2004; Rawlings et al. 2012). The height of each stack in the 
sequence logo indicates the sequence conservation, as measured in bits, at that amino acid subsite, and the 
height of the letter indicates the relative frequency of the corresponding amino acid at the subsite.  
 
 
both proteins (Malm et al. 2000). Using 
substrate phage display and iterative 
optimization of semenogelin cleavage sites,  
Coombs and coworkers showed that the 
sequence SS(Y/F)Y ↓ S(G/S) is optimal for 
efficient cleavage by PSA (Coombs et al. 
1998). Tryptic cleavage sites (cleavage after 
Arg and Lys) have been reported in some 
studies, but this is very likely a matter of 
contaminations caused by other proteases in 
the PSA preparations. Indeed, commercially 
available PSA preparations have been found 
to contain trypsin-like contaminations 
(Manning et al. 2012). 
 
4.6 Biological function of PSA 
The main physiological function of PSA is to 
cleave the gel-forming proteins semeno-
gelins I and II, and fibronectin in seminal 
fluid (Lilja 1985; Lilja et al. 1987). Several 
other biological functions have been 
suggested for PSA, mostly based on the 
proteolytic cleavage of different protein 
substrates (Table 1) (reviewed in Borgono 
and Diamandis 2004; Lawrence et al. 2010).  
The proposed functions of PSA may be 
relevant for prostate cancer development, but 
the suggestions are contradictory, since some 
promote prostate cancer growth, invasion or 
metastasis, while others inhibit these 
(Diamandis 2000; Borgono and Diamandis 
2004; Williams et al. 2007). The biological 
significance of cleavage of many PSA 
substrates remains to be confirmed in vivo. 
Most of the suggested functions are based on 
in vitro studies and should be interpreted 
with caution, as isolated cancer cell lines do 
not behave in the same way as cancer cells in 
the tumor microenvironment (Bissell and 
Hines 2011). It is also noteworthy that the 
purity of the PSA preparations in different 
studies varies and some preparations may be 
contaminated by other proteases, such as 
KLK2 and trypsin (Paju et al. 2000; Manning 
et al. 2012). The enzymatic activity of the 
PSA preparations has not always been tested 
properly and controlled for in these studies 
(Williams et al. 2011).  
 
Liquefaction of seminal clot 
Semenogelins secreted by the seminal 
vesicles are the major protein components of 
seminal fluid (Lilja et al. 1987; Malm et al. 
1996). Semenogelin I and semenogelin II 
have a 78% identity at the amino acid level 
and both contain similar 60-amino acid long 
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Table 1. Putative protein substrates and inhibitors of PSA. Most of the functions proposed for PSA 
lack validation. 
Substrate Proposed function Reference 
Semenogelin I  Seminal clot liquefaction (Lilja 1985) 
Semenogelin II Seminal clot liquefaction (Lilja 1985) 
Fibronectin ECM degradation, invasion, metastasis and 
seminal clot liquefaction 
(Lilja et al. 1987) 
Laminin ECM degradation, invasion and metastasis (Webber et al. 1995) 
Collagen type IV ECM degradation (Pezzato et al. 2004) 
IGFBP-3 Release of IGF-I, increased cell proliferation (Cohen et al. 1992) 
Galectin-3 Angiogenesis, metastasis, cell proliferation (Saraswati et al. 2011) 
Plasminogen Angiogenesis inhibition (Heidtmann et al. 1999) 
PTHrP Bone metastasis (Cramer et al. 1996; 
Iwamura et al. 1996) 
Latent TGF-β2 Bone metastasis, tumor growth +/- (Dallas et al. 2005) 
Insulin A and B, 
Interleukin-2, 
Fibrinogen, Gelatin, 
Myoglobin, Ovalbumin 
Diverse (Watt et al. 1986) 
α1-antichymotrypsin 
(ACT) 
Inhibition of PSA activity (Lilja et al. 1991; Stenman et 
al. 1991) 
α1-protease inhibitor 
(API) 
Inhibition of PSA activity (Zhang et al. 1997) 
α2-macroglobulin 
(A2M) 
Inhibition of PSA activity (Zhang et al. 2000) 
Protein C inhibitor  Inhibition of PSA activity (Espana et al. 1991; 
Christensson and Lilja 1994) 
 
repetitive units (Lilja and Lundwall 1992). 
Together with fibronectin, they are 
responsible for semen coagulation, which 
occurs immediately after ejaculation and 
traps the spermatozoa inside the coagulum 
(Lilja et al. 1987; Robert and Gagnon 1999; 
Veveris-Lowe et al. 2007). The coagulum 
formation is thought to protect the 
spermatozoa from the acidic environment of 
the female reproductive tract (reviewed in 
Robert and Gagnon 1999; Veveris-Lowe et 
al. 2007). Within minutes, the seminal clot is 
liquefied by proteolysis of the gel-forming 
proteins – here PSA is the major proteolytic 
enzyme (Lilja 1985; Lilja et al. 1987) – and 
motile spermatozoa are released progres-
sively to pass through the female 
reproductive tract to the site of fertilization 
(Lilja et al. 1989). PSA cleaves semeno-
gelins very effectively, with 18 reported 
cleavage sites in semenogelin I and 16 in 
semenogelin II (Malm et al. 2000). 
Allosteric reversible binding of Zn2+ 
regulates the liquefaction of semen by 
inhibiting PSA activity in the prostate and 
prostatic fluid (Watt et al. 1986; Malm et al. 
2000). As semenogelins I and II have a high 
Zn2+-binding capacity, mixing of prostatic 
fluid with seminal fluid during ejaculation 
results in redistribution of Zn2+ to 
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semenogelins and activation of PSA (Malm 
et al. 2000; Jonsson et al. 2005). 
In addition to formation of the seminal 
clot, semenogelins and their degraded 
fragments exert various other functions 
during fertilization. Semenogelins directly 
inhibit sperm motility by arresting the 
flagellar movement of the spermatozoa, 
activate sperm hyaluronidase, regulate 
sperm capacitation and exert antimicrobial 
activity (reviewed in Robert and Gagnon 
1999; de Lamirande 2007; Veveris-Lowe et 
al. 2007). Thus, the cleavage of semeno-
gelins by PSA may have a range of 
consequences which together impact on 
fertility. 
 
Degradation of ECM proteins and invasion 
PSA degrades ECM proteins fibronectin 
(Lilja et al. 1987; Webber et al. 1995), 
laminin (Webber et al. 1995) and collagen 
type IV (Pezzato et al. 2004), as well as other 
unidentified ECM proteins of the Matrigel 
basement membrane preparation (Ishii et al. 
2004). Due to its ability to cleave ECM 
proteins, PSA might induce invasion and 
metastasis in prostate cancer, as degradation 
of the basement membrane and ECM are the 
first steps required for invasion. The 
invasion of PSA-expressing LNCaP prostate 
cancer cells in vitro was also reduced, when 
the activity of PSA was inhibited by an 
antibody or Zn2+ (Webber et al. 1995; Ishii et 
al. 2004). 
Epithelial to mesenchymal transition 
(EMT) is thought to be involved when the 
cancer progresses towards an invasive 
phenotype (reviewed in Kalluri and 
Weinberg 2009; Thiery et al. 2009). PSA, 
transfected into PC3 prostate cancer cells, 
induced EMT-like changes by altering cell 
morphology and promoting motility 
(Veveris-Lowe et al. 2005). PSA-transfected 
cells also had a decreased E-cadherin and 
increased vimentin gene expression, both 
typical changes associated with EMT. 
PSA stimulates also a cold receptor, the 
transient receptor potential melastatin 8 
(TRPM8), through the bradykinin 2 receptor 
signaling pathway, resulting in reduced PC3 
prostate cancer cell migration (Gkika et al. 
2010). 
 
Functions related to cell proliferation and 
tumor growth 
The IGF system consists of IGF-I and IGF-
II, their membrane bound receptors and 
several IGF-binding proteins (IGFBP), and 
is involved in the development of many 
cancers (reviewed in Samani et al. 2007). 
IGFBP-3, which is a major carrier of IGF-I 
in the circulation, prolongs the half-life and 
regulates the binding of IGF-I to its receptor 
(reviewed in Jogie-Brahim et al. 2009). PSA 
degrades IGFBP-3 and thus releases active 
IGF-I bound to IGFBP-3 (Cohen et al. 1992). 
Free IGF-I stimulates cell proliferation and 
may increase prostate cancer growth (Cohen 
et al. 1992; Cohen et al. 1994; Jogie-Brahim 
et al. 2009). Independent of IGF-I, IGFBP-3 
or its fragments inhibit cell growth and 
angiogenesis, and induce apoptosis (Oh et al. 
1993; Rajah et al. 1997; Silha et al. 2006; Liu 
et al. 2007). Increased IGF-I and decreased 
IGFBP-3 levels may be associated with an 
increased prostate cancer risk (Chan et al. 
1998), but not all studies on this subject have 
documented an association (Finne et al. 
2000; Jogie-Brahim et al. 2009) and even 
opposite results have been reported, i.e., that 
high levels of IGFBP-3 have been associated 
with an increased risk of prostate cancer 
(Severi et al. 2006). PSA cleaves also 
IGFBP-4, but not IGFBP-2 or IGFBP-5 
(Rehault et al. 2001).  
PSA is associated with bone metastasis 
of prostate cancer, which is in keeping with 
the observation that PSA stimulates 
proliferation and differentiation of osteo-
blasts, induces apoptosis in osteoclast 
precursors and induces expression of several 
osteogenic genes in human osteosarcoma 
SaOS-2 cells (Killian et al. 1993; Goya et al. 
2006; Nadiminty et al. 2006). PSA degrades 
and, thus, inactivates parathyroid hormone-
related protein (PTHrP), which may cause 
hypercalcemia in cancer and is involved in 
bone resorption mediated by osteoclasts 
(Cramer et al. 1996; Iwamura et al. 1996). 
The small latent form of TGF-β2 is cleaved 
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and activated by PSA (Killian et al. 1993; 
Dallas et al. 2005). TGF-β2 has both tumor 
growth-promoting and growth-preventing 
activities. The activation of IGF-I and TGF-
β2 and inactivation of PTHrP suggest that 
PSA may play a role in the formation of 
osteoblastic bone metastases in prostate 
cancer (Dallas et al. 2005; Williams et al. 
2007). PSA hydrolyzes also insulin A and B, 
interleukin-2, gelatin, myoglobin, ovalbu-
min and fibrinogen (Watt et al. 1986), but the 
biological relevance of this remains to be 
studied. 
PSA has been proposed to exert many 
functions related to cancer growth, in 
addition to those associated with the 
proteolytic cleavage of specific substrates. 
Although the expression of PSA is decreased 
in cancer (Abrahamsson et al. 1988), high 
levels of enzymatically active PSA are 
present in the extracellular fluid of the 
prostate and this may influence cancer 
growth (Denmeade et al. 2001; Williams et 
al. 2011). 
Some studies have shown that PSA 
increases cancer cell proliferation, e.g., PSA 
transfection into (androgen responsive) 
LNCaP and CWR22rv1 prostate cancer cells 
increased cell proliferation (Niu et al. 2008). 
Stable transfection of RNA interference 
constructs, causing a 95% reduction of PSA 
expression in LNCaP cells, decreased 
significantly cell proliferation both in vitro 
and in vivo (Williams et al. 2011). PSA has 
also been proposed to reduce apoptosis, as 
knockdown of endogenous PSA by small 
interfering RNA (siRNA)-transfection 
resulted in suppression of cell growth and 
increase in cell death in LNCaP and 
CWR22rv1 cells (Niu et al. 2008). However, 
PSA had no effect on the proliferation of 
PC3 prostate cancer cells (Fortier et al. 
1999), but PSA did inhibit the growth of 
PC3M xenograft tumors in nude mice, when 
administered subcutaneously adjacent to the 
tumor (Bindukumar et al. 2005). 
In transgenic mice expressing PSA in 
their prostate, PSA did not cause any 
morphological changes or signs of prostate 
cancer, suggesting that PSA does not initiate 
prostate cancer development (Williams et al. 
2010). However, the PSA levels in these 
mice were several orders of magnitude lower 
than in the human prostate. It has not been 
possible to generate PSA knockout mice 
because rodents lack PSA-encoding gene 
(Lundwall et al. 2006; Lawrence et al. 2010).  
Treatment of the prostate cancer cell 
lines PC3M and LNCaP with enzymatically 
active PSA induced changes in the 
expression of several cancer-related genes 
(Bindukumar et al. 2005; Bindukumar et al. 
2008). PSA down-regulated the expression 
of tumor growth-promoting genes, including 
vascular endothelial growth factor (VEGF), 
uPA and the Pim-1 oncogene, and up-
regulated the expression of tumor 
suppressive genes, such as interferon-γ 
(Bindukumar et al. 2005).  
Further, PSA stimulates the production 
of reactive oxygen species in prostate cancer 
cells (Sun et al. 2001) and is associated with 
immunosuppressive (Kennedy-Smith et al. 
2002; Aalamian et al. 2003) and proinflam-
matory functions (Kodak et al. 2006).  
 
Antiangiogenic activity of PSA  
The antiangiogenic activity of PSA was first 
reported by Fortier and coworkers (Fortier et 
al. 1999). PSA, purified from seminal 
plasma, inhibits fibroblast growth factor 
(FGF)-stimulated proliferation of human 
umbilical vein endothelial cells (HUVEC), 
bovine adrenal capillary endothelial cells 
and human microvascular dermal cells in a 
dose-dependent fashion, but does not affect 
the proliferation of murine melanoma or 
human prostate cancer cells (PC3). PSA 
reduces growth factor-stimulated migration, 
invasion and tube formation of HUVECs, 
while the protease inhibitor ACT abolishes 
the inhibition of migration. PSA also inhibits 
angiogenesis in vivo in a Matrigel plug 
model (Fortier et al. 2003).  
The mechanism of the antiangiogenic 
effect of PSA has not been fully elucidated. 
It is controversial whether proteolytic 
activity is even needed for the antiangiogenic 
activity of PSA. A recombinant variant of 
PSA with a single amino acid deletion in the 
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N-terminus was studied (Fortier et al. 2003). 
It lacked proteolytic activity against a small 
chromogenic PSA substrate, but had 
antiangiogenic effects in vitro and inhibited 
neovascularization in a Matrigel plug model 
in vivo. Recently, it was reported that both 
enzymatically active PSA and PSA 
inactivated by Zn2+ inhibited tube formation, 
migration and invasion of endothelial cells, 
and suppressed the expression of growth 
factors, such as VEGF and bFGF in 
HUVECs (Chadha et al. 2011). However, the 
amount of Zn2+ used in the study has not 
totally inhibited PSA in other studies at the 
reported concentrations (Malm et al. 2000).  
An in vitro study showed that PSA 
cleaves plasminogen into angiostatin-like 
fragments, which inhibit endothelial cell 
tube formation (Heidtmann et al. 1999). 
These fragments were suggested to mediate 
the antiangiogenic effect of PSA. However, 
PSA might produce also other angiogenesis 
inhibitors by proteolytic cleavage of several 
ECM molecules (Mattsson et al. 2009). In 
another study, PSA has been found to cleave 
plasminogen and to produce active plasmin 
(de Souza et al. 2013).  
PSA cleaves galectin-3, which is a 
carbohydrate-binding protein present in 
seminal fluid associated with cell growth, 
angiogenesis and metastasis in prostate 
cancer (Wang et al. 2009; Saraswati et al. 
2011). Galectin-3 stimulates endothelial cell 
tube formation in vitro and angiogenesis in 
vivo (Nangia-Makker et al. 2000). A 
collagenase-cleaved 21 kDa fragment of 
galectin-3 inhibits VEGF- and bFGF-
mediated angiogenesis induced by the full-
length galectin-3 in vitro and in vivo 
(Markowska et al. 2010). The cleavage by 
PSA results in a 16 kDa fragment of 
galectin-3 (Saraswati et al. 2011) and leads 
to inhibition of functions stimulated by the 
full-length protein, e.g., endothelial cell 
morphogenesis and prostate cancer cell 
migration (Balan et al. 2012). In addition, 
phosphorylation of galectin-3 regulates its 
cleavage, as PSA cannot cleave galectin-3 
when the cleavage site is phosphorylated 
(Balan et al. 2012). The expression of 
galectin-3 is associated with metastatic 
potential in many cancers, but it is 
downregulated in prostate cancer (Pacis et al. 
2000; Takenaka et al. 2004). 
Clinical studies imply that it is more 
likely that PSA has a suppressive rather than 
a growth-promoting effect on prostatic 
tumors. PSA levels in malignant prostatic 
tissue are lower than in healthy prostatic 
tissue and expression is further reduced as 
the aggressiveness of the tumor increases 
(Abrahamsson et al. 1988; Pretlow et al. 
1991; Magklara et al. 2000; Paju et al. 2007). 
Also, a low tissue PSA concentration 
measured in fine-needle aspiration biopsy 
samples of prostate cancer patients was 
found to be associated with an adverse 
prognosis (Stege et al. 2000). Furthermore, 
high PSA levels in prostate cancer tissue are 
associated with a low microvessel density 
(Papadopoulos et al. 2001) and low 
angiogenesis activity, as determined by 
immunohistochemical staining with CD34 
antibody (Ben Jemaa et al. 2010). Recently, 
the enzymatic activity of PSA in prostatic 
fluid was also found to be inversely 
associated with the aggressiveness of 
prostate cancer (Ahrens et al. 2013) 
 
4.7 Clinical use of PSA   
PSA as a biomarker  
PSA was first identified in seminal fluid as 
“γ-seminoprotein” in 1966 and was used as a 
forensic marker for identification of semen, 
e.g., in rape cases (Hara et al. 1971). During 
the following years several groups 
independently discovered the substance in 
seminal fluid and prostate tissue, and 
different names were given: E1, P30 and 
prostate antigen (Li and Beling 1973; 
Sensabaugh 1978; Wang et al. 1979). Wang 
and coworkers first purified PSA from 
prostatic tissue and named it prostate-
specific antigen (Wang et al. 1979). It was 
later shown to be identical with γ-
seminoprotein, E1 and P30 (Sensabaugh and 
Blake 1990; Wang et al. 1994).  
Papsidero and coworkers developed a 
radioimmunoassay for PSA and showed that 
PSA is present in the serum of men with 
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metastatic prostate cancer (Papsidero et al. 
1980) – the utility of PSA as a cancer marker 
was discovered. In 1987, Stamey et al. 
analyzed the clinical usefulness of PSA and 
showed that the concentration of PSA in the 
serum of patients with prostate cancer 
increased with advancing clinical stage and 
tumor volume (Stamey et al. 1987). They 
also showed that the level of PSA could be 
used to monitor the response to therapy and 
to detect recurrence after radical prostatec-
tomy and radiation therapy (Stamey et al. 
1987). Catalona and coworkers demon-
strated the utility of the serum PSA test for 
screening of prostate cancer (Catalona et al. 
1991). 
Disruption of the tissue architecture in 
prostate cancer increases the leakage of PSA 
from the prostate into circulation, which 
raises the level of PSA in the serum. Because 
the background level of PSA in healthy men 
is low, PSA is the best biomarker of prostate 
cancer presently available (Stenman et al. 
1999a; Stenman et al. 2005; Lilja et al. 
2008). However, PSA is not cancer specific; 
the level of PSA in the serum rises also in 
BPH and prostatitis (Stamey et al. 1987). 
The usual PSA test measures total PSA 
(tPSA) in serum. Large cohort studies have 
shown that prostate cancer is detected by 
needle biopsy in 27 - 44% of patients with a 
PSA level > 4 µg/L (Crawford et al. 1996; 
Hugosson et al. 2004; Andriole et al. 2005). 
The threshold of 4 µg/L has, however, been 
criticized, since also lower levels of PSA are 
associated with a considerable risk of 
prostate cancer (Thompson et al. 2004; Aus 
et al. 2005). Very low PSA concentrations 
can also occur due to deletions in the KLK3 
gene, which can lead to false-negative PSA 
findings (i.e., not able to detect cancer when 
cancer is present) (Rodriguez et al. 2013). 
When enzymatically active PSA reaches 
the circulation, it is rapidly bound by 
protease inhibitors such as A2M and ACT in 
the plasma. Internally cleaved or “nicked” 
PSA does not react with protease inhibitors 
and remains free in circulation. In prostate 
cancer, the proportion of fPSA is lower and 
that of PSA-ACT is higher than in BPH 
patients and in healthy men (Stenman et al. 
1991; Christensson et al. 1993). The 
measurement of free or complexed PSA or 
the proportion of the free to total PSA 
(%fPSA) in the serum is thus a useful way to 
improve the specificity of PSA as a detector 
of prostate cancer (Stenman et al. 2005). If 
the total PSA level is 4 - 10 µg/L and there is 
more than 25% of fPSA, the risk of cancer is 
low, but if %fPSA is below 15%, the risk of 
cancer is increased (Finne et al. 2008). 
Although tPSA alone is not a specific marker 
for prostate cancer diagnosis, it is a very 
reliable indicator of cancer recurrence after 
therapy (Stamey et al. 1993).  
Men who later in life develop prostate 
cancer have higher PSA levels than controls 
already several decades before the clinical 
symptoms (Fang et al. 2001; Whittemore et 
al. 2005). The concentration of PSA in the 
serum in men younger than 50 years predicts 
prostate cancer diagnosis 20 to 30 years later 
(Lilja et al. 2011). The PSA velocity, i.e., the 
rate at which serum PSA level increases over 
time, is another useful marker of an 
increased risk of prostate cancer (Carter et al. 
1992; Carter et al. 2006; Loeb et al. 2007). 
The PSA concentrations in the serum 
increase above the cut-off level 5 to 10 years 
before the tumor surfaces clinically 
(Stenman et al. 1994).  
The utility of PSA as a screening tool for 
prostate cancer has been studied in Europe 
and the USA (Andriole et al. 2012; Schroder 
et al. 2012b), but the results of these trials 
and the benefits of screening are 
controversial (Moyer 2012). The European 
Randomized Study of Screening of Prostate 
Cancer (ERSPC) has shown that screening 
based on PSA reduces mortality and the risk 
of developing metastatic prostate cancer 
(Schroder et al. 2012a; Schroder et al. 
2012b), but another study conducted in the 
USA, the Prostate, Lung, Colorectal, and 
Ovarian (PLCO) Cancer Screening Trial, did 
not find evidence of reduced mortality 
(Andriole et al. 2012). The latter study has, 
however, been criticized for several 
drawbacks (Schroder and Roobol 2010; 
Thorek et al. 2013). In both studies screening 
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was shown to lead to a rate of overdiagnosis 
of about 50%, i.e., detection of cancers that 
would not have surfaced clinically during the 
patients’ lifetime (Draisma et al. 2003). 
Overdiagnosis leads to overtreatment, which 
may cause serious side effects and reduce the 
quality of life of the patient (Loeb et al. 
2014). Because of its questionable benefit, 
the United States Preventive Services Task 
Force has made a recommendation against 
screening of PSA in healthy men (Moyer 
2012). 
 
PSA as a therapeutic target  
PSA is a potential therapeutic target for 
prostate cancer, since PSA is expressed 
mainly in the prostate and there are high 
concentrations of active PSA present locally 
only around prostate tumors. Several PSA 
inhibitors and stimulators based on either 
antibodies, peptides or small molecule 
compounds have been developed (reviewed 
in Goettig et al. 2010; Swedberg et al. 2010; 
LeBeau et al. 2010; Sotiropoulou and 
Pampalakis 2012; Mavridis et al. 2014). 
Monoclonal antibodies that stimulate or 
inhibit PSA activity have been developed by 
several groups (Nilsson et al. 1999). Peptides 
that bind specifically to PSA and stimulate 
its enzymatic activity have been developed 
by phage display technology using cyclic 
peptide libraries (Wu et al. 2000). These 
peptides do not bind to other similar 
proteases or enzymatically inactive PSA 
(Wu et al. 2000). The peptides were 
suggested to bind near the active site of PSA 
and to stabilize the kallikrein loop (Wu et al. 
2000; Pakkala et al. 2004; Koistinen et al. 
2008). The stability of these peptides has 
been improved by an alternative cyclization 
method (Pakkala et al. 2010) and by 
peptidomimetic approaches, in which part of 
the peptide is replaced by non-peptidic 
structures. This gives rise to pseudopeptides 
with retained bioactivity (Meinander et al. 
2013). Also other peptides that bind to PSA 
have been identified by phage display. Both 
cyclic and linear peptide libraries have been 
used, but these peptides stimulate only the 
activity of immobilized PSA, not of PSA in 
solution (Ferrieu-Weisbuch et al. 2006). 
The first synthetic small molecule 
compounds modulating the activity of PSA 
were inhibitors, such as β-lactam compounds 
(Adlington et al. 2001) and azapeptides 
(Huang et al. 2001). Subsequently, highly 
selective boronic acid-based inhibitors were 
developed for PSA (LeBeau et al. 2008). 
One of these inhibits PSA from degrading its 
protein substrates, inhibits the growth of 
prostate cancer cells and reduces slightly the 
growth of prostate cancer xenografts in vivo 
(LeBeau et al. 2008). The first small 
molecule compound shown to stimulate PSA 
activity was identified by pharmacophore-
based virtual screening (Härkönen et al. 
2011).  
Protease-activated prodrugs that can be 
used to deliver drugs into a specific tissue 
have also been developed for PSA 
(Denmeade et al. 1998; DeFeo-Jones et al. 
2000). Prodrugs are inactive drug constructs 
containing a cytotoxic drug molecule that is 
conjugated to a peptide sequence, which 
upon cleavage by a protease (in this case 
PSA) releases the active drug molecule in the 
target tissue (reviewed in Choi et al. 2012; 
Mavridis et al. 2014). For treatment of 
prostate cancer, the most promising prodrug 
is a doxorubicin-conjugate labeled L-
377,202 which selectively kills PSA-
producing human prostate cancer cells and 
inhibits the growth of tumor xenografts in 
mice (DeFeo-Jones et al. 2000). L-377,202 
has been studied in phase I and II clinical 
trials and the results have been promising 
(DiPaola et al. 2002).  
Several vaccines have been developed 
against prostate cancer, some of which target 
PSA (reviewed in Geary and Salem 2013). 
The relatively slow growth of prostate cancer 
allows vaccines to develop immune 
responses and highly prostate-specific 
proteins, such as PSA, are ideal targets for 
vaccination. For example, a viral-based 
vaccine against PSA, PROSTVAC, and a 
DNA-based vaccine, DNA-PSA, have been 
well tolerated by patients in clinical trials. In 
a phase II trial of PROSTVAC, the survival 
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of the patients with prostate cancer was 
prolonged by 8.5 months (Pavlenko et al. 
2004; Kantoff et al. 2010). 
If new treatments for prostate cancer 
with PSA as a therapeutic target are to be 
developed, the function of PSA in normal 
physiology and in prostate cancer must be 
clearly understood. 
 
5. Angiogenesis 
During embryonic development the first 
blood vessels are formed in a process called 
vasculogenesis, where endothelial precursor 
cells (angioblasts) differentiate to 
endothelial cells that form a primary 
capillary plexus, a primitive network of 
endothelial tubes (reviewed in Risau and 
Flamme 1995) (Figure 5). After this, 
endothelial cells start forming new blood 
vessels from the pre-existing ones, in a 
process called angiogenesis, which is 
characterized both by sprouting and 
branching of the pre-existing vessels and by 
splitting them through intussusception 
(reviewed in Carmeliet and Jain 2011). 
Sprouting angiogenesis is the most common 
mode of blood vessel formation. 
Lymphangiogenesis, the sprouting of 
lymphatic vessels from pre-existing lymph 
vessels, is a process similar to angiogenesis 
and shares signaling pathways and 
molecules that are interconnected in a 
delicate and complex manner (Adams and 
Alitalo 2007; Lohela et al. 2009). 
In the adult, the normal vasculature is 
mostly quiescent, but angiogenesis takes 
place in many physiological processes, e.g., 
during the female reproductive cycle and in 
wound healing. Angiogenesis is also 
associated with many diseases. While 
abnormal, excessive angiogenesis is typical 
for cancer and inflammatory disorders, 
insufficient angiogenesis can cause 
cardiovascular diseases and pre-eclampsia 
(Carmeliet 2005).  
 
5.1 Tumor angiogenesis 
Angiogenesis is essential for tumor growth, 
since tumor cells, like any other cells in 
normal tissues, need blood vessels to provide 
them with oxygen and nutrients, and to re-
move metabolites. Metastatic dissemination 
requires also blood vessels.  
Angiogenesis is one of the hallmarks of 
cancer and the “angiogenic switch”, i.e., the 
ability of the tumor to induce blood vessel 
growth, is a crucial step in cancer 
progression (Hanahan and Folkman 1996; 
Hanahan and Weinberg 2000; Bergers and 
Benjamin 2003; Baeriswyl and Christofori 
2009; Hanahan and Weinberg 2011). Under 
physiological conditions, angiogenesis is 
tightly regulated by various pro- and 
antiangiogenic factors, but the balance 
between activators and inhibitors becomes 
disrupted when the “angiogenic switch” 
occurs in a tumor and the level of activators 
exceeds that of inhibitors.  
The research on tumor angiogenesis 
started to expand when Folkman (1971) 
proposed that tumor growth is dependent on 
angiogenesis and announced that a tumor 
cannot grow larger than 1 - 2 mm3 unless it 
induces the growth of new blood vessels.  He 
also proposed that blood vessel growth is 
stimulated by angiogenic factors secreted by 
the tumor and that fighting against 
angiogenesis could be useful for cancer 
therapy.  
Tumor blood vessels are structurally and 
functionally abnormal when compared to 
normal vasculature (Jain 2005; Goel et al. 
2011; Potente et al. 2011). Tumor vessels are 
irregular, leaky, dilated in diameter, not 
hierarchically organized like normal vessels 
and the vascular density varies in different 
parts of the tumor. As a result, the supply of 
oxygen and nutrients, as well as of drugs, 
through the tumor vasculature is not very 
efficient. This stimulates the tumor to 
produce continuously proangiogenic factors. 
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Figure 5. Development of the vascular system, mechanism of sprouting angiogenesis and structure of blood 
vessels (modified from Carmeliet 2005; Welti et al. 2013). Endothelial progenitor cells form a primitive vascular 
network during vasculogenesis. Angiogenesis is the formation of new blood vessels from pre-existing ones by 
sprouting and branching. Sprouting angiogenesis is stimulated by proangiogenic factors attracting endothelial 
cells to form elongations. Endothelial tip cells with filopodia respond and migrate along the gradients of 
proangiogenic stimuli, while stalk cells proliferate and form the lumen of the sprouting vessel. Attached to the 
basement membrane, endothelial cells cover the inner wall, as pericytes and smooth muscle cells line the outer 
wall of the blood vessel. The ECM flanks the vessels from the outside. Some of the known proangiogenic and 
antiangiogenic factors are shown.  
 
 
Hypoxia, the insufficient oxygen supply in 
the tumor tissue, and oncogene activation 
trigger increased production of hypoxia- 
inducible factor-1 (HIF-1), which is 
considered to be a key regulator of 
angiogenesis (reviewed in Harris 2002; 
Carmeliet and Jain 2011). HIF-1 induces 
expression of several genes encoding 
proangiogenic factors in the tumor cells, the 
most important one being VEGF (Ferrara 
2009; Claesson-Welsh and Welsh 2013). 
VEGF activates signal transduction 
pathways by binding to VEGFR-2 and 
regulates vessel sprouting by inducing 
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endothelial cell proliferation and migration. 
Also other members of the VEGF-family and 
their receptors are involved in the complex 
signaling pathways in both angiogenesis and 
lymphangiogenesis (Adams and Alitalo 
2007; Ferrara 2009). There are several other 
proangiogenic growth factors involved in 
angiogenesis including FGF, platelet-
derived growth factor (PDGF), placental 
growth factor (PlGF), angiopoietins-1 and 
- 2, and TGF-β (Carmeliet and Jain 2011), as 
well as many endogenous angiogenesis 
inhibitors, e.g., thrombospondin-1 and -2, 
angiostatin and endostatin (Folkman 2006; 
Kazerounian et al. 2008).  
Tumor cells induce vessel sprouting, as 
the proangiogenic growth factors attract 
endothelial cells to form extensions, which 
consist of migrating tip cells at the leading 
edge of the sprout and proliferating stalk 
cells situated just behind the tip cells 
(reviewed in Potente et al. 2011; Welti et al. 
2013) (Figure 5). Filopodia of the tip cells 
sense the gradients of the angiogenic 
guidance cues and lead tip cell migration 
along these gradients, while stalk cells form 
the lumen of the elongating vessel. Tip cells 
of one branch fuse with tip cells of another 
branch to form a new blood vessel. Among 
many other molecules involved in vessel 
sprouting, VEGF and Notch/DLL4 form the 
main regulatory signaling systems and 
maintain a fine-tuned crosstalk with each 
other (Adams and Alitalo 2007; Potente et al. 
2011). 
 
5.2 Proteases in angiogenesis 
In the angiogenic processes, various 
proteases interact with the cells of the 
vascular system, ECM and its specialized 
form, the basement membrane (Figure 5). 
Endothelial cells line the inner walls of blood 
vessels, while mural cells (pericytes or 
vascular smooth muscle cells) surround the 
endothelial cells by forming the outer vessel 
walls. The basement membrane, to which 
both of these cells are attached, lies in 
between the cell layers and the ECM 
surrounds the vessels providing structural 
support for cells and tissues among its many 
other functions. The ECM and the basement 
membrane consist of numerous proteins, and 
their molecular composition varies in 
different tissues. The major components of 
the vascular basement membrane include 
collagen type IV, laminins, nidogens (also 
known as entactins) and heparan-sulfate 
proteoglycans, while the minor components 
are collagen type XV and XVIII, fibulins and 
osteonectin (reviewed in Kalluri 2003; 
Arnaoutova et al. 2009; Hynes 2009). 
Signaling between the cells and the matrix 
occurs through complex signaling networks 
that involve integrins and receptor tyrosine 
kinases, but also through proteolytic 
cleavage and exposure of internal cryptic 
sites (Clause and Barker 2013). 
In sprouting angiogenesis, proteases are 
needed in the initial phase of vessel 
branching in a process called matrix 
remodeling (Campbell et al. 2010; 
Kessenbrock et al. 2010). Proteases remodel 
the basement membrane and ECM by direct 
proteolytic degradation of matrix proteins 
and this enables mural and endothelial cells 
to detach from the basement membrane, to 
migrate and to form new blood vessels. 
Proteases can also promote angiogenesis by 
releasing active growth factors, such as 
VEGF, FGF, PDGF and TGF-β, which are 
bound by various ECM proteoglycans and 
thus stored within the matrix, and by 
exposing proangiogenic cryptic domains of 
ECM components that are hidden in the 
protein structure and become bioavailable 
after proteolytic cleavage (Kalluri 2003; 
Carmeliet and Jain 2011). However, 
degradation of ECM proteins can also lead to 
inhibition of angiogenesis. Some of the ECM 
molecules contain cryptic domains that exert 
antiangiogenic activity, when proteolytically 
released from their parent ECM protein. 
Such antiangiogenic fragments include 
endostatin, arrestin, canstatin and tumstatin 
(Kalluri 2003; Nyberg et al. 2005). 
Several proteases are involved in 
angiogenesis and have both proangiogenic 
and antiangiogenic functions, many of them 
belonging to the protease families of the 
MMPs, ADAM/TS, the uPA/uPAR system 
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and cathepsin cysteine proteases (reviewed 
in Mohamed and Sloane 2006; Rocks et al. 
2008; Kessenbrock et al. 2010; Mason and 
Joyce 2011; Breuss and Uhrin 2012). 
MMP-2, -9 and -14 may play a 
significant role in angiogenesis (reviewed in 
Rundhaug 2005; Kessenbrock et al. 2010). 
Suppression of MMP-2 inhibits angiogene-
sis in vivo in a chicken chorioallantoic 
membrane model (Fang et al. 2000), while 
MMP-9 expression is required for the 
angiogenic switch, as it releases VEGF 
bound by ECM molecules (Bergers et al. 
2000). Different MMPs may have 
overlapping functions and certain MMPs can 
also exert different actions in different 
tissues depending on their expression and the 
substrates available at a certain time 
(Kessenbrock et al. 2010; Littlepage et al. 
2010). At least MMP-2, -3, -7, -9 and -12 
generate the angiogenesis inhibitor 
angiostatin from plasminogen (Dong et al. 
1997; Patterson and Sang 1997; Cornelius et 
al. 1998; O'Reilly et al. 1999), while MMP-
3, -7, -9, - 12, -13 and -20 cleave the 
endostatin fragment from collagen type 
XVIII (Ferreras et al. 2000; Heljasvaara et al. 
2005). 
ADAM/TS regulate angiogenesis 
directly or through activation of MMPs 
(Rocks et al. 2008; Campbell et al. 2010). An 
angiogenesis-promoting role has been 
ascribed at least to ADAM-17 (Gooz et al. 
2009), while ADAMTS-1, -5 and -8 were 
shown to inhibit angiogenesis in several 
angiogenesis models (Vazquez et al. 1999; 
Sharghi-Namini et al. 2008). The uPA/uPAR 
system, in which uPA binds to its receptor 
uPAR and cleaves plasminogen, thus 
generating active plasmin, was proposed to 
promote angiogenesis by activation of 
growth factors such as VEGF and bFGF, by 
degradation of ECM components and by 
activation of other proteases such as MMPs 
(reviewed in Pepper 2001; Blasi and 
Carmeliet 2002; Breuss and Uhrin 2012). 
However, uPA can also generate angiostatin 
from plasminogen (Gately et al. 1997; 
Westphal et al. 2000). Several cathepsins and 
elastases are also involved in angiogenesis, 
e.g., by generating endostatin from collagen 
type XVIII (Wen et al. 1999; Felbor et al. 
2000). 
 
5.3 Angiogenesis inhibitors 
Endogenous angiogenesis inhibitors 
Endogenous angiogenesis inhibitors are 
proteins or protein fragments that occur 
naturally and are able to inhibit blood vessel 
formation (reviewed in Nyberg et al. 2005; 
Ribatti 2009). The matrix-derived angiogen-
esis inhibitors originate from the ECM, 
while the non-matrix-derived inhibitors are 
mainly growth factors and cytokines or 
fragments of blood coagulation factors. 
Angiogenesis inhibition takes place via 
different pathways, mainly through 
inhibition of endothelial cell proliferation or 
migration, or through induction of apoptosis. 
These pathways are complex and not yet 
fully characterized, as individual antiangio-
genic factors have been found to utilize 
several mechanisms to fulfil their function 
(Tabruyn and Griffioen 2007; Ribatti 2009). 
The endothelial cell surface integrins often 
act as receptors for angiogenesis inhibitors, 
and especially integrin αvβ3 is an important 
angiogenesis stimulator. Integrins mediate 
various intracellular signalling pathways 
which regulate cell survival, proliferation 
and migration (Eliceiri and Cheresh 1999). 
A large multimeric ECM glycoprotein, 
thrombospondin-1, was the first protein to be 
identified as a naturally occurring 
angiogenesis inhibitor (Good et al. 1990). 
Thrombospondin-1 binds to CD36 and integ-
rin αvβ3, inhibits endothelial cell migration 
and induces endothelial cell apoptosis by 
influencing VEGF activity either directly or 
through MMPs (Kazerounian et al. 2008). 
Thrombospondin-2 has been shown to have 
similar antiangiogenic functions as throm-
bospondin-1.  
Endostatin is a 20 kDa C-terminal 
fragment of collagen type XVIII that inhibits 
proliferation and migration, and causes 
apoptosis of endothelial cells (O'Reilly et al. 
1997; Yamaguchi et al. 1999). Its antiangio-
genic activities are mediated through 
interaction with several cell surface 
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receptors including integrins α5β1 and αvβ3, 
and heparan sulfate proteoglycans (Faye et 
al. 2009). Among many other mechanisms 
that may mediate its antiangiogenic 
functions, endostatin has been found to 
interfere with VEGF-signaling, and to 
directly bind to MMP-2 and inhibit its 
activity (reviewed in Tabruyn and Griffioen 
2007). Endostatin also down-regulates many 
proangiogenic genes and up-regulates 
antiangiogenic genes of several signalling 
pathways (Tabruyn and Griffioen 2007).  
There are also several other collagen-
derived antiangiogenic fragments, including 
arresten, canstatin and tumstatin, that are 
generated from collagen type IV (reviewed 
in Nyberg et al. 2005; Mundel and Kalluri 
2007; Monboisse et al. 2014). Arresten is a 
26 kDa fragment of the C-terminal non-
collagenous domain of the α1 chain of 
collagen type IV that binds to integrin α1β1 
and inhibits endothelial cell proliferation and 
migration (Colorado et al. 2000; Sudhakar et 
al. 2005). Canstatin, a 24 kDa fragment of 
the α2 chain of collagen type IV, inhibits 
migration and induces apoptosis by binding 
to integrins αvβ3 and αvβ5 (Kamphaus et al. 
2000; Magnon et al. 2005). Tumstatin, a 
28 kDa fragment of the α3 chain of collagen 
type IV released mainly by MMP-9, induces 
apoptosis and inhibits proliferation and 
protein synthesis of endothelial cells by 
binding to integrin αvβ3 (Maeshima et al. 
2000; Hamano et al. 2003). Several small 
peptides from collagen type IV chains α4, α5 
and α6 have also been shown to exert 
antiangiogenic activity (Karagiannis and 
Popel 2007). Other matrix-derived 
angiogenesis inhibitors include a perlecan 
fragment, endorepellin (Mongiat et al. 2003), 
and a fibronectin fragment, anastellin (Yi 
and Ruoslahti 2001). 
Angiostatin, the internal fragment of 
plasminogen, is one of the most intensely 
studied non-matrix-derived endogenous 
angiogenesis inhibitors (O'Reilly et al. 
1994). Angiostatin is a 38 - 45 kDa molecule 
consisting of either three or four N-terminal 
kringle domains of plasminogen. Several 
MMPs, elastases, uPA and tissue 
plasminogen activator (tPA), are able to 
generate angiostatin (Gately et al. 1997; Cao 
and Xue 2004). The mechanism of the 
antiangiogenic action of angiostatin is at 
least partially known: angiostatin binds to 
several proteins and it affects various 
signalling pathways on the endothelial cell 
surface and thus mediates apoptosis, cell 
cycle arrest and inhibition of proliferation, 
migration and tube formation (reviewed in 
Geiger and Cnudde 2004; Wahl et al. 2005; 
Tabruyn and Griffioen 2007). Angiostatin 
inhibits adenosine triphosphate (ATP)-
synthesis by binding to ATP-synthase and 
triggers caspase-mediated apoptosis in 
endothelial cells (Moser et al. 1999; 
Veitonmäki et al. 2004). Angiostatin also 
binds to integrin αvβ3 (Tarui et al. 2001) and 
to angiomotin, which induces focal adhesion 
kinase activity, and thus inhibits endothelial 
cell migration (Troyanovsky et al. 2001). In 
addition, angiostatin alters the expression of 
several genes involved in proliferation, 
inflammation, apoptosis and migration in 
HUVECs (Chen et al. 2006). 
Other non-matrix-derived angiogenesis 
inhibitors include interleukins, interferons, 
pigment epithelium derived factor (PEDF), 
antithrombin III and prothrombin kringle 2, 
platelet factor-4, TIMPs, chondromodulin, 
2-methoxyestradiol, a 16 kDa prolactin 
fragment, a fragment of MMP-2 (PEX), 
troponin I and vasostatin (reviewed in 
Nyberg et al. 2005; Ribatti 2009). 
 
Angiogenesis-inhibiting drugs 
The angiogenesis inhibitors used for therapy 
can be divided into three groups according to 
the number of the targets they block: single-
target, multi-target and broad-spectrum 
inhibitors (Folkman 2007; Limaverde-Sousa 
et al. 2014). The focus of antiangiogenic 
drug research has been on the development 
of VEGF and VEGFR inhibitors which block 
the VEGF-signaling pathway. Multi-target 
tyrosine kinase inhibitors, such as sorafenib 
and sunitinib have been approved by the US 
Food and Drug Administration for clinical 
use, as well as the most widely used single-
target inhibitor, the anti-VEGF antibody 
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bevacizumab (Ferrara 2009; Carmeliet and 
Jain 2011; Potente et al. 2011; Welti et al. 
2013). Anti-VEGF therapy reduces abnor-
mal vessel formation and remodels the 
remaining vessels. This results in a 
“normalized vasculature”, which also 
sensitizes tumor vessels to cytotoxic and 
radiation therapies (Goel et al. 2011; Potente 
et al. 2011).  
Despite the promising outlook of the 
anti-VEGF therapies in preclinical studies, 
challenges have arisen as the drugs have 
entered clinical use, as some patients do not 
respond and others develop resistance to 
anti-VEGF therapy. Even if the patients 
respond, these drugs prolong survival with 
only few months and the efficacy varies 
between different cancer types (Carmeliet 
and Jain 2011). Tumors can acquire 
resistance to anti-VEGF treatment by 
inducing other proangiogenic molecules and 
may exploit, instead of sprouting 
angiogenesis, other modes of vasculariza-
tion, such as intussusception and vessel co-
option (Bergers and Hanahan 2008; Ebos 
and Kerbel 2011). Anti-VEGF therapy may 
also enhance tumor metastasis through 
increased hypoxia (Carmeliet and Jain 2011; 
Potente et al. 2011; Shojaei 2012). So far, the 
best results of antiangiogenic treatment have 
been obtained by a combination of anti-
VEGF and cytotoxic therapies (Ebos and 
Kerbel 2011; Potente et al. 2011; Limaverde-
Sousa et al. 2014). 
Apart from the VEGF-pathway, growth 
factor receptors, integrins and other 
endothelial cell surface molecules may serve 
as alternative targets for antiangiogenic 
therapy (Fayette et al. 2005; Limaverde-
Sousa et al. 2014). Broad-range endogenous 
angiogenesis inhibitors, e.g., angiostatin and 
endostatin, are promising candidates for 
next-generation antiangiogenic drugs. 
Several recombinant proteins, peptides and 
synthetic antiangiogenic agents have been 
developed on the basis of endogenous 
inhibitors and are in the preclinical or early 
clinical phase of drug development, and only 
a few have been approved for treatment thus 
far. One of the approved drugs is a modified 
recombinant endostatin, Endostar, which has 
been approved for clinical use in 
combination with chemotherapy in China 
(Fu et al. 2009).  
 
5.4 Angiogenesis models  
Several different models have been used to 
study the mechanisms of angiogenesis and to 
test pro- and antiangiogenic molecules. 
These models include various in vitro assays 
which provide models of proliferation, 
migration and tube formation of endothelial 
cells (reviewed in Staton et al. 2009). Most 
often HUVECs or microvascular endothelial 
cells are used in these assays. Co-culture 
assays of endothelial cells grown together 
with other cells of the tumor microenviron-
ment, such as fibroblasts, tumor cells or 
pericytes, have also been developed. 
The most widely used in vitro assay is 
an endothelial cell tube formation model, 
which is relatively inexpensive, reliable, 
rapid and easy to perform (Kubota et al. 
1988; Arnaoutova and Kleinman 2010). In 
this assay, endothelial cells differentiate in 
the presence of growth factors, such as epi-
dermal growth factor (EGF) and FGF, into 
capillary-like tubular networks containing a 
lumen. This takes place within 16 - 20 hours 
after plating the cells on a gelled reconsti-
tuted basement membrane such as Matrigel, 
an extract of basement membrane proteins 
derived from the mouse Engelbreth-Holm-
Swarm sarcoma (Kleinman and Martin 
2005). Tube formation is usually quantified 
by measuring either the average tube length, 
the number of tubes, the area covered by the 
tubular network, the number of branch points 
or combinations of these. There are also 
other tube formation models that use 
collagen or fibrin matrix, as well as three-
dimensional spheroid models that recapitu-
late in vivo angiogenesis more faithfully than 
the two-dimensional models (Laib et al. 
2009). The rat aortic ring assay is an example 
of an ex vivo model, in which explants of rat 
aorta cultured in a gelled matrix form 
sprouting vessels (Nicosia and Ottinetti 
1990).  
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Traditional in vivo models of angiogenesis 
include the chick chorioallantoic membrane 
assay, the corneal angiogenesis assay and the 
Matrigel plug assay (reviewed in Norrby 
2006; Staton et al. 2009). The Matrigel plug 
assay is a commonly used model, in which 
Matrigel that may contain the tested 
angiogenic agent, is subcutaneously injected 
into mice where it forms a plug. Later the 
plug is removed and the amount of blood 
vessels grown inside the plug is determined. 
The zebrafish (Danio rerio) that has large 
transparent embryos, has been adapted to a 
whole animal model of angiogenesis 
(Norrby 2006). Various tumor models have 
also been developed for studying 
angiogenesis in mice, including tumor cell 
transplantation (human xenograft) models 
and transgenic mouse models, such as the 
RIP1-Tag2 pancreatic islet tumor model 
(Eklund et al. 2013). 
Different models have their strengths 
and limitations. In vitro models based on 
endothelial cells are well suited for large 
scale screening of pro- and antiangiogenic 
molecules, but these models recapitulate 
generally only certain aspects of the 
angiogenic process and lack the influence of 
other cell types. Ex vivo models represent the 
tissue microenvironment better, but are less 
suitable for screening, while in vivo models 
serve better for functional studies and for 
evaluating the clinical relevance of the pro- 
and antiangiogenic compounds. However, 
these are more expensive and laborious and 
not all of them are suitable for large scale 
screenings.  
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AIMS OF THE STUDY  
The aim of this study was to characterize the antiangiogenic and proteolytic properties of PSA 
in relation to prostate cancer development. One of the major objectives was to elucidate 
whether the enzymatic activity of PSA is needed for its antiangiogenic activity. This was part 
of a wider goal to reveal the mechanism by which PSA exerts its antiangiogenic activity at the 
molecular level. Elucidation of this mechanism would improve the understanding of prostate 
tumor growth. With an increased understanding of the function of PSA, new opportunities for 
the treatment of prostate cancer may arise. 
 
The main goals of the study were: 
 
1. To characterize the antiangiogenic activity of PSA in an in vitro angiogenesis model and to 
study the molecular mechanism of this activity. 
2. To study the proteolytic activity of PSA toward different protein and peptide substrates. 
3. To study the effect of the PSA-stimulating peptides on the antiangiogenic and proteolytic 
activities of PSA. 
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MATERIALS AND METHODS 
1. Proteins, peptides and other 
compounds  
The proteins, antibodies, peptides, small 
molecule compounds and peptide substrates 
used in this work are listed in Table 2.  
Peptides that bind to PSA and stimulate 
its activity were identified by screening of 
phage display peptide libraries (Wu et al. 
2000). Synthetic peptides were purchased 
from several manufacturers and the purity of 
all batches was > 95% as measured by high-
performance liquid chromatography 
(HPLC). Different modifications of peptide 
B2, i.e., with and without C-terminal 
amidation (B2-NH2 and B2, respectively) 
and corresponding inactive derivatives (B2-
NH2-control and B2-control), were also 
used.  
Two compounds which inhibit PSA 
activity (benzoxazinone derivative A1 and 
triazole-containing compound B1) were 
found by screening of a library of 49,920 
small drug-like compounds (mostly 
300 - 400 Da). Compounds A1, B1 and B3 
(a derivative of B1) obtained from 
Chembridge (compound IDs 7569902, 
7797337 and 7828958, respectively) were 
used in the cell culture experiments. 
 
1.1 Purification of PSA (I-V) 
PSA was purified from pooled human 
seminal plasma by immunoaffinity 
chromatography, and the different isoforms 
(PSA-A’, -A, -B, -C, -D and -E) were 
isolated by anion-exchange chromatography 
as described (Zhang et al. 1995; Wu et al. 
2004a). Briefly, seminal plasma was 
precipitated with ammonium sulfate at 25% 
saturation and the precipitate was discarded. 
The remaining solution was precipitated at 
70% saturation of ammonium sulfate, the 
precipitate was collected by centrifugation 
and dissolved in 50 mM Tris buffer, pH 7.8, 
containing 0.05% sodium azide and applied 
to an immunoaffinity column with anti-PSA 
monoclonal antibody (mAb) (either 5E4 or 
4G10) coupled to CNBr-activated Sepharose 
(Amersham Pharmacia Biotech). PSA was 
eluted with 0.2% trifluoroacetic acid (TFA) 
followed by neutralization with Trizma base. 
Further isolation of different PSA isoforms 
was performed by anion-exchange chroma-
tography. Briefly, immunoaffinity-purified 
PSA was diluted in 10 mM Tris-HCl buffer, 
pH 8.7, containing 0.05% sodium azide 
(buffer A) and applied to a Resource Q 
column (Amersham Biosciences). PSA 
isoforms were eluted with a linear gradient 
of buffers A and B (buffer A containing 
0.3 M NaCl) (see Figure 6A). 
ProPSA was isolated from LNCaP cell 
culture medium by immunoaffinity chroma-
tography with anti-PSA mAb 4G10 coupled 
to CNBr-activated Sepharose and separated 
further by ion-exchange chromatography. 
Immunoaffinity-purified LNCaP PSA was 
dialyzed against 50 mM phosphate buffer, 
pH 5.8 (buffer C) and applied to a Resource 
S column (Amersham Pharmacia Biotech). 
ProPSA was eluted with a linear gradient of 
buffers C and D (buffer C containing 0.4 M 
NaCl). The enzymatic activity of the proPSA 
preparation was low, ~ 7% of the activity of 
PSA-B (Wu et al. 2004b).  
 
2. Assays for the enzymatic activity of 
PSA (I-V) 
The enzymatic activity of PSA was 
measured using two small peptide substrates, 
the detection of which is based either on a 
chromogenic or fluorogenic signal resulting 
from cleavage of the peptide moiety. The 
chromogenic substrate is cleaved both by 
chymotrypsin and PSA, while the 
fluorogenic substrate was identified as a 
PSA-specific substrate (Denmeade et al. 
1997) (Table 2).  
To determine the enzymatic activity of 
different PSA isoforms in cell culture 
samples, a fluorogenic assay was performed 
in duplicates in black 384-well microplates 
(Corning). Samples of cell culture medium 
were incubated with 0.3 mM fluorogenic 
substrate in 50 mM Tris, pH 7.7, containing 
0.15 M NaCl (TBS) and 1 g/l bovine serum 
albumin  (0.1%  BSA-TBS)  for  4 h  at  room 
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Table 2. Proteins, antibodies, peptides, small molecule compounds and peptide substrates. 
Proteins Description Study Source/reference 
PSA (isoform PSA-B) enzymatically active PSA, isolated from 
human seminal fluid 
I-V (Zhang et al. 1995; Wu 
et al. 2004a) 
PSA isoforms A’, A, C, D, E enzymatically active (A’ and A) and 
partially active (C-E) PSA, isolated from 
human seminal fluid 
I (Zhang et al. 1995; Wu et 
al. 2004a) 
ProPSA enzymatically inactive precursor of PSA, 
isolated from LNCaP cell culture medium 
I, II (Wu et al. 2004a) 
α-chymotrypsin from bovine pancreas I, V Sigma-Aldrich, Millipore  
MMP-3 catalytic domain, recombinant human V Calbiochem  
Semenogelins I and II isolated from human seminal fluid V (Malm et al. 1996) 
Fibronectin from human plasma V BD Biosciences  
IGFBP-3 recombinant human V PeproTech  
Galectin-3 recombinant human V R&D Systems  
Nidogen-1 recombinant human V R&D Systems 
Plasminogen from human plasma V Hyphen BioMed, 
American Diagnostica, 
Calbiochem 
Antibodies Description Study Source 
5C7 monoclonal anti-PSA antibody (inhibits 
PSA activity) 
I-III, V (Stenman et al. 1999b) 
5E4 monoclonal anti-PSA antibody I-V (Stenman et al. 1999b) 
4G10 monoclonal anti-PSA antibody I-V (Stenman et al. 1999b) 
AF2570 polyclonal goat anti-nidogen-1 antibody  V R&D Systems 
P0449  horseradish peroxidase-conjugated 
secondary antibody, rabbit anti-goat IgG 
V Dako  
M0616 monoclonal mouse anti-human von 
Willebrand factor antibody 
I-V Dako 
Peptides Sequence Study Source 
PSA-stimulating peptides   (Wu et al. 2000) 
B2 CVFAHNYDYLVC (cyclic, disulfide bridge 
between C1-C12) 
II, V Anaspec, GenScript, 
BioMatik 
B2-NH2 CVFAHNYDYLVC-NH2 (cyclic, as B2) V GenScript 
C4 CVAYCIEHHCWTC (double cyclic, 
disulfide bridges between C1-C13 and 
C5-C10) 
II, V NeoMPS, BioMatik 
Control peptides    
B2-control CVFAHNADALVC (cyclic, as B2) II Anaspec 
B2-NH2-control CVFAHNADALVC-NH2 (cyclic, as B2) V Biomatik 
Compounds Description Study Source 
A1 (7569902) 2-(2-methyl-3-nitrophenyl)-4H-3,1-
benzoxazin-4-one 
III Chembridge 
B1 (7797337) 1-(3,4-dimethoxybenzoyl)-3-(3-
pyridinyl)-1H-1,2,4-triazol-5-amine 
III Chembridge 
B3 (7828958) 1-(4-methoxybenzoyl)-3-(3-pyridinyl)-
1H-1,2,4-triazol-5-amine 
III Chembridge 
Peptide substrates Description Study Source 
Chromogenic PSA 
substrate S-2586 
MeO-Suc-Arg-Pro-Tyr-pNA V Chromogenix, Peptides 
International 
Fluorogenic PSA substrate 4-morpholinecarbonyl-HSSKLQ-
amidomethylcoumarin (AMC)  
I-V (Denmeade et al. 1997), 
JPT Peptide Technologies 
GmbH, ChemPep Inc. 
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temperature and fluorescence was measured 
at 355/460 nm (excitation/emission) with a 
Victor 1420 Multilabel plate reader 
(PerkinElmer). 
The enzyme kinetics of PSA was studied 
both with chromogenic and fluorogenic 
substrates. The assays were performed in 
clear 96-well (PerkinElmer) or black 384-
well (Corning) microplates in duplicates in 
0.1% BSA-TBS at room temperature. 
Different concentrations of the chromogenic 
or fluorogenic substrate (0.125 - 5 mM) 
were incubated with 175 nM PSA-B. For 
studies on the effect of the PSA-stimulating 
peptides, 350 nM PSA and peptides with 
different concentrations (0.35 - 350 µM) 
were pre-incubated for 30 min at room tem-
perature, after which 0.2 mM chromogenic 
or 0.3 mM fluorogenic substrate was added. 
The absorbance at 405 nm was measured at 
5 min intervals for 30 min and fluorescence 
at 355/460 nm after 10 min, 20 min, 40 min, 
1 h, 2 h and 4 h incubation, as described 
above. 
Vmax, Km and kcat were determined using 
Sigma Plot 11 with the Enzyme Kinetics 
Module 1.3 (SYSTAT Software). The 
Lambert-Beer equation (A = εcl) was used to 
convert absorbance to molar concentration, 
with the molar absorptivity of pNA 
(εpNA = 8800 M - 1 cm - 1). A standard curve 
for 7-amido-4-methylcoumarin (AMC, 
Sigma-Aldrich) was used to transform 
fluorescence (counts per second, cps) to 
molar concentration.  
 
3. Peptide binding assay (V) 
The interaction of the peptides with PSA was 
studied using surface plasmon resonance 
(SPR) on a Biacore T100 instrument using 
Biacore T100 Control Software 2.0.3 (GE 
Healthcare) at the Biacore Core Facility 
(Division of Biochemistry and Biotechnol-
ogy, Department of Biosciences, University 
of Helsinki). PSA or α-chymotrypsin 
(20 µg/ml), were covalently immobilized on 
the Series S Sensor Chip CM5 (GE 
Healthcare) using amine coupling in 10 mM 
sodium acetate buffer, pH 5.0. Peptides 
(1.2 - 600 µM) were diluted in phosphate-
buffered saline (PBS), pH 7.4, containing 
6.7 mM PO4 and 0.15 M NaCl (Lonza). 
Binding took place at a flow rate of 
40 µl/min at 25 °C. The binding data was 
analyzed using Biacore T100 Evaluation 
software 2.0.3. (GE Healthcare) with a 
Steady State Affinity model (n = 3 for B2 
and n = 4 for B2-NH2 and C4).  
 
4. Proteolytic activity of PSA toward 
protein substrates 
4.1 Degradation of Matrigel (V) 
Matrigel extracted from Engelbreth-Holm-
Swarm mouse sarcoma (BD Biosciences), 
containing 9.7 mg/ml of ECM proteins, was 
diluted in TBS. Diluted Matrigel (250 µg/ml 
of ECM proteins) was incubated with PSA 
(200 µg/ml, 7.1 µM) at 37 °C for 48 h and a 
sample containing 5 µg of digested ECM 
proteins and 4 µg of PSA was analyzed by 
sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) followed by 
silver staining or Western blotting. 
 
4.2 Degradation of protein substrates (V) 
Protein substrates (0.5 - 1 µM) were incu-
bated with 0.2 - 1 µM PSA at 37 °C in TBS 
buffer and samples were drawn after 0 min, 
10 min, 30 min, 2 h, 5 h and 22 h incubation. 
As a control, plasminogen was also incu-
bated with 1 µM MMP-3 for 22 h. In order 
to demonstrate that the cleavage of protein 
substrates resulted only from the proteolytic 
activity of PSA, the activity of PSA was 
inhibited by pre-incubation for one hour with 
a two-fold molar excess of mAb 5C7 before 
incubation with the protein substrates. 
The stimulating effect of the PSA-
binding peptides on the proteolytic activity 
of PSA toward protein substrates was also 
studied. First, 0.2 µM PSA was pre-incu-
bated for 30 min at room temperature with 1 
or 5 µg of peptides B2 and C4 (46 or 230 µM 
and 43 or 213 µM, respectively). Protein 
substrates (0.3 - 2.5 µM) were added to the 
PSA-peptide mixture and incubated at 37 °C 
for 10 min (semenogelin I), 40 min (semeno-
gelin II), 4 h (fibronectin and nidogen-1) or 
20 - 22 h (galectin-3 and IGFBP-3).  
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Reducing 4 x SDS-loading buffer, contain-
ing 0.25 M Tris-HCl, pH 6.8, 8% SDS, 40% 
glycerol, 1 M β-mercaptoethanol or 75 mM 
dithiothreitol and 0.01% bromophenol blue, 
was added to each sample after incubation, 
proteins were denatured at 70 °C for 10 min 
and samples were either analyzed directly by 
SDS-PAGE followed by silver staining or 
frozen at -20 °C. The degradation of 
proteins, i.e., the disappearance of the full-
length protein bands, was analyzed from 
silver stained gels using ImageJ (Schneider 
et al. 2012). 
 
4.3 Assay for the degradation of IGFBP-
3 (V) 
A sandwich-type immunofluorometric assay 
(IFMA) measuring only intact IGFBP-3 was 
used to study the degradation of IGFBP-3 by 
PSA (Koistinen et al. 1994; Koistinen et al. 
2002). IGFBP-3 (2.2 µM) was incubated 
with 0.2 µM PSA at 37 °C for 24 h in TBS 
buffer, with and without 1 or 5 µg of peptides 
B2 and C4 (46 or 230 µM and 43 or 213 µM, 
respectively). Thereafter, samples were 
diluted 1:1000 in IFMA assay buffer and 
IGFBP-3 concentrations were measured as 
previously described. 
 
5. SDS-PAGE, silver staining and 
Western blotting (V) 
SDS-PAGE was performed using the XCell 
SureLock Mini Cell system and pre-cast 
NuPAGE Novex 4 - 12 % Bis-Tris Gels 
(both from Invitrogen) with MES running 
buffer, pH 7.3, containing 50 mM MES 
[2- (N-morpholino) ethanesulfonic acid], 
50 mM Tris base, 3.5 mM SDS and 1 mM 
EDTA. Proteins were detected by silver 
staining (modified from Yan et al. 2000) 
directly from the gels or by Western blotting 
after transferring to an Immobilon-P 
membrane (Millipore) by the Trans Blot 
semi-dry transfer system (BioRad 
Laboratories). The membrane was blocked 
with 1% BSA in TBS over night at 4 °C and 
incubated with 0.1 µg/ml goat anti-
nidogen- 1 polyclonal antibody (AF2570, 
R&D Systems) over night at 4 °C, prior to 
detection with horseradish peroxidase-
conjugated rabbit anti-goat IgG (P0449, 
Dako) and enhanced chemi-luminescence 
detection reagents (GE Healthcare). 
 
6. Mass spectrometry 
6.1 Characterization of PSA isoforms (I) 
PSA isoforms were desalted by reverse-
phase (RP)-HPLC on a C4 column 
(Symmetry C4, 3.9 mm x 20 mm, 300 Å, 
5 µm, Waters) and eluted with a linear 
gradient of acetonitrile (ACN) (0 – 80% in 
30 min) in 0.1% TFA. Mass spectrometry 
(MS) was performed with a Q-TOF Micro 
(Waters) with electrospray ionization (ESI).  
PSA isoforms were either injected 
directly into the MS via a nanoflow interface 
with a Hamilton-syringe pump at a flow rate 
of 0.3 ml/min or in-liquid reduced with 
dithiothreitol and alkylated with 4-
vinylpyridine (Aldrich) in 6 M guanidine 
hydrochloride, 2 mM EDTA in 0.5 M Tris, 
pH 7.5. Prior to the MS analysis, the 
alkylated PSA isoforms were further 
fractionated and desalted by RP-HPLC on a 
C4 column as described above. The MS was 
calibrated using 400 fmol/µl myoglobin 
(Sigma) as a standard. Protein mass was 
calculated after deconvolution with 
MassLynx 4.0 (Waters). 
 
6.2 Identification of Matrigel-derived 
PSA substrates (V)  
Selected protein fragments that were 
digested from Matrigel by PSA were cut 
from the silver-stained gel, alkylated and 
digested with modified trypsin (V511A, 
Promega) as described (Shevchenko et al. 
1996). Peptide fragments were purified using 
ZipTipC18 (Millipore), eluted with 3 µl of 
40% ACN in 0.1% TFA and diluted with 
21 µl of 0.1% formic acid (FA). Extracted 
peptides were separated on a RP-HPLC 
(CapLC, Waters) with a C18 trap column 
(Atlantis dC18, NanoEase Trap Column, 
5 µm, Waters) and a 0.075 x 150 mm C18 
analytical column (Atlantis dC18, 100 Å, 
3 µm, Waters) and eluted with a linear 
gradient of ACN (5 - 50% in 30 min) in 
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0.1% FA at a flow rate of 0.3 µl/min. The 
MS was calibrated using 2 pmol/µl 
glufibrinogenic peptide B fragments and the 
LC-MS repeatability was validated using a 
commercial standard BSA-digest (Waters). 
MS analysis was performed online with a Q-
TOF Micro (Waters) with an ESI source. 
Proteins were identified using Progenesis 
LC-MS 2.4 (Nonlinear Dynamics) and 
Mascot search engine 2.2. 
 
7. Edman degradation (V) 
N-terminal sequencing was performed to 
determine the sites cleaved by PSA in the 
nidogen-1 sequence. Nidogen-1 (1 µM) was 
incubated with 2 µM PSA for 22 h at 37 °C 
in TBS buffer and the resulting fragments 
were separated by SDS-PAGE and 
electroblotted onto polyvinylidene-difluo-
ride membrane. Protein fragments were 
stained with Coomassie Brilliant Blue and 
sequenced using the Procise 494A 
Sequencer (Perkin Elmer Applied 
Biosystems) at the Proteomics Unit Core 
Facility (Institute of Biotechnology, 
University of Helsinki). 
 
8. Cell culture  
8.1 LNCaP cells (I) 
LNCaP cells, derived from a human prostate 
carcinoma lymph node metastasis, were 
obtained from ATCC (CRL-1740). Cells 
were grown in RPMI 1640 cell culture 
medium (Cambrex) supplemented with 10% 
fetal bovine serum (HyClone), 1.5 g/l 
sodium bicarbonate, 4.5 g/l glucose, 10 mM 
HEPES, 1 mM sodium pyruvate (Sigma 
Aldrich), and 1% non-essential amino acids, 
2 mM L-glutamine and 1% penicillin-
streptomycin (Cambrex). 
 
8.2 Human umbilical vein endothelial 
cells (I-V) 
Human umbilical vein endothelial cells 
(HUVEC) were isolated from umbilical cord 
veins by digestion with 0.3 mg/ml 
collagenase type IV (440 U/mg) essentially 
as described (Jaffe et al. 1973). Cells were 
grown in Endothelial Cell Growth Medium 
containing 2% fetal calf serum (FCS), 0.4% 
endothelial cell growth supplement/heparin, 
0.1 ng/ml EGF, 1 ng/ml bFGF and 1 µg/ml 
hydrocortisone (Promocell). Cell culture 
medium was supplemented with 50 µg/ml 
gentamycin and 0.5 µg/ml amphotericin B 
(Sigma-Aldrich or Promocell). For serum-
free conditions FCS was replaced by 2% 
Ultroser G BioSepra serum substitute (PALL 
BioSepra).  
At passage 1, cells were tested for von 
Willebrand factor-positivity by immuno-
staining with a monoclonal mouse anti-
human von Willebrand factor antibody 
(M0616, Dako). HUVECs were frozen at 
passage 1 or 2, passaged at least once after 
thawing and used for experiments between 
passages 4 and 8. The culture flasks and 
wells were coated with 0.2% gelatin. 
 
HUVEC tube formation assay (I-V) 
Four-chamber cell culture slides (BD 
Biosciences) were coated with 150 µl 
Matrigel basement membrane preparation 
(BD Biosciences) and incubated for 30 min 
at 37 °C. HUVECs (1 - 1.5 x 105) were 
added on top of Matrigel in 0.7 ml culture 
medium together with 0.01 - 1 µM PSA-B, 
0.1 µM of other PSA isoforms or 0.1 µM α-
chymotrypsin (Sigma Aldrich). To study the 
gene expression on a microarray analysis, 
the tube formation assay was performed on 
6-well cell culture plates (Corning) coated 
with 800 µl Matrigel and 0.7 x 106 cells were 
added in 3 ml culture medium.  
Either 100 µM PSA-stimulating 
peptides (B2 or C4) or 80 µM PSA-
inhibitors were added to the cells with and 
without PSA. Also, 10 µg/ml nidogen-1 or 
galectin-3, or their PSA-cleaved fragments, 
after the inhibition of PSA activity with 
mAb 5C7, were added to the cells. Control 
wells contained either PBS, TBS, 0.1 µM 
proPSA, 100 µM inactive control peptide 
(B2-control) or PSA, the activity of which 
was inhibited by two-fold molar excess of 
mAb 5C7. HUVECs were grown on 
Matrigel for 16 - 18 h allowing complete 
tube formation. All samples in the assays 
were performed in duplicate and the 
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enzymatic activity of PSA was measured at 
the beginning and end of each experiment 
using the fluorogenic substrate.  
To study the mechanism of the 
antiangiogenic effect of PSA, cell culture 
medium was collected from PSA-treated or 
untreated cells after 18 h incubation on 
Matrigel and PSA activity was inhibited by 
mAb 5C7, as confirmed by measurement of 
the enzymatic activity using fluorogenic 
substrate. The conditioned medium was then 
used to grow new tubular networks on 
Matrigel for 18 h.  
Live cell images (100x magnification) 
were acquired with an Axiovert 200 inverted 
light microscope using a digital AxioCam 
camera and Axiovision software (Zeiss). 
HUVEC tube formation was quantified by 
measuring the average area covered by the 
tubular network from five live cell images 
per each well by Image-Pro Plus 6-image 
analysis software (Media Cybernetics Inc.) 
(I, II). In order to better quantify the effect of 
various treatments on the angiogenic 
potential of the cells, quantification analysis 
was refined: in each image the number of all 
closed structures of the tubular network that 
were not disrupted were counted and the 
number was multiplied with the tube area of 
the corresponding image. This yielded a 
value called angiogenesis index (III) (Figure 
14). 
 
Phalloidin staining (I) 
HUVECs grown on Matrigel were fixed with 
ice-cold acetone-methanol (1:1) for 10 min 
at 4 °C. Cells were permeabilized with 0.2% 
Triton-X in PBS and the actin filaments were 
stained with TexasRed-X phalloidin 
(Invitrogen Molecular Probes) diluted 1:80 
in 0.1% BSA in PBS for 20 min at room 
temperature. The cells were mounted with 
Vectashield-DAPI mounting medium 
(Vector Laboratories), which also stained the 
cell nuclei. Images were acquired with an 
Axioplan 2 epifluorescence microscope as 
described above. 
 
 
 
8.3 Proliferation and viability assays (I) 
Proliferation of HUVECs was studied using 
the colorimetric BrdU Cell Proliferation 
ELISA kit (Roche Applied Science). 
HUVECs (8,000 cells/well) were plated on 
gelatin-coated 96-well cell culture plates and 
incubated with or without 0.1 µM PSA-B for 
18 h. Then cells were incubated with the 
BrdU-labeling reagent for 3 h, and prolifer-
ating cells were detected with an anti-BrdU 
antibody according to the manufacturer’s 
instructions. 
Cell viability of HUVEC and LNCaP 
cells was studied using CellTiter-Glo 
Luminescent Cell Viability Assay 
(Promega). This assay is based on 
quantification of ATP produced by 
metabolically active cells. HUVECs (6,000 
or 10,000 cells/well) were grown on gelatin-
coated wells and LNCaP cells (14,000 or 
20,000 cells/well) on Matrigel-coated wells 
of 96-well cell culture plates, and incubated 
with or without 0.1 µM PSA-B for 18 h. 
Thereafter, CellTiter-Glo Reagent was 
added and luminescence measured according 
to the manufacturer’s instructions. 
 
9. Immunoassays for endostatin and 
angiostatin  
The levels of endostatin and angiostatin were 
measured in the HUVEC culture medium of 
PSA-treated and control cells using the 
Quantikine Human Endostatin Immunoassay 
(R&D Systems) and Human Angiostatin 
ELISA Kit (PromoKine). HUVECs were 
grown on Matrigel with and without 0.5 µM 
PSA for 18 h after which cell culture 
medium was collected and stored at -20 °C. 
All samples (n = 3) were analyzed in 
duplicates.  
 
10. Gene expression analyses (IV) 
10.1 RNA isolation, DNA microarray 
and data analysis 
RNA was isolated from PSA-treated and 
control HUVECs grown on Matrigel. Cells 
were separated by dissolving Matrigel with 
Cell Recovery Solution (BD Biosciences) by 
incubation on ice for 70 min. RNA-isolation 
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was performed by RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. 
Cells were lysed with lysis buffer containing 
1% β-mercaptoethanol (Sigma Aldrich), and 
the lysates were centrifuged through a 
QIAshredder spin column (Qiagen). DNA 
was digested on-column using an RNase-
Free DNase Set (Qiagen) and RNA eluted 
with 30 µl RNase-free water. The RNA 
integrity number (RIN) and RNA concentra-
tion in the samples were measured using 
Agilent 2100 bioanalyzer (Agilent 
Technologies), and all samples contained 
high-quality RNA (RIN 9.5-10). 
Gene expression was analyzed using 
Agilent Whole Human Genome Oligo 
Microarray 4x44K (G4112F, Agilent Tech-
nologies) (containing 41,000 unique genes 
and transcripts) at the Biomedicum Biochip 
Center core facility (University of Helsinki, 
Finland). Total RNA (1 µg) was labeled 
using the RNA input fluorescent linear 
amplification kit (Agilent Technologies) and 
hybridized on the microarray chip according 
to the manufacturer’s instructions. Data was 
pre-processed using the Feature Extraction 
software (7.5.1). 
Differential gene expression between 
PSA-treated and control cells was analyzed. 
Genes, in which the difference in mean 
hybridization signals was less than 200, were 
excluded from the data, as this was 
considered background noise. To identify 
whether there were analogous or opposite 
gene expression changes in other studies, the 
200 most up-regulated and 200 most down-
regulated genes (≥ 1.5-fold up-regulation or 
down-regulation and p < 0.05) were selected. 
Of these, 156 up-regulated and 146 down-
regulated genes had Ensembl gene IDs and 
were compared with two relevant studies 
found in the Gene Expression Omnibus 
(GEO) database. These two studies, which 
were performed with Affymetrix Human 
Genome arrays, concerned endothelial cell 
proliferation and tubulogenesis (GEO 
accession number GSE3891) (Glesne et al. 
2006) and the treatment of endothelial cells 
by growth factors VEGF and PGF (GSE837) 
(Schoenfeld et al. 2004). Genes with ≥ 1.5-
fold up-regulation and down-regulation were 
chosen from these studies and analysis was 
performed by using the statistical software 
environment R (R Development Core Team, 
2007).  
Also, the 200 most up-regulated and 200 
most down-regulated genes were compared 
manually to gene expression changes 
reported to be induced in endothelial cells by 
angiostatin (15 up- and 134 down-regulated 
genes) and endostatin (47 up- and 93 down-
regulated genes) (GSE2177) (Cline et al. 
2002). WebGestalt, a Web-based Gene Set 
Analysis Toolkit (Zhang et al. 2005), was 
used to analyze the gene expression data in 
the Gene ontology (GO) and Kyoto 
Encyclopedia of Genes and Genomes 
(KEGG) databases.  
 
10.2 Quantitative RT-PCR  
RNA (1 µg) was converted to cDNA by 
reverse transcription using M-MLV reverse 
transcriptase (Promega) and a random 
hexamer primer. cDNA (1 µl) was amplified 
in four identical reactions by RT-PCR using 
Power SYBR Green PCR Master Mix on an 
ABI Prism 7500 FAST instrument (Applied 
Biosystems). PCR primers were designed 
using the Primer3 program (Rozen and 
Skaletsky 2000): 5’-CGT GAT CTC CCC 
TCA CAC TT-3’ and 5’-GTT TCT CAT 
CCA GGC AGC TC-3’ for PGF; 5’-AAA 
GAG TGA TCG CCA GAG GA-3’ and 5’-
TCA AAT GAG CAG AGC GAA TG-3’ for 
P25; 5’-GTG CTC GCG CTA CTC TCT 
CT-3’ and 5’-TTC AAT GTC GGA TGG 
ATG AA-3’ for B2M; 5’-GAC CAG TCA 
ACA GGG GAC AT-3’ and 5’-CCT GAC 
CAA GGA AAG CAA AG-3’ for HPRT1; 
5’-GCG GGT GAG ATG TGG TCT AT-3’ 
and 5’-GCT GAG GGG CAG AGA GAG 
TA-3’ for HES7; 5’-CTA CTG CAG CCA 
CCC TTC TC-3’ and 5’-CAG GAA GTA 
GGC ACC GAG AG-3’ for BMP8A; 5’-
CAG CTG ACC AGG ACT GTGAA-3’ and 
5’-TGT AGA AGG GAA ACG CTG CT-3’ 
for CYR61; and 5’-AAT GCC GCT GAG 
TAT CTG CT-3’ and 5’-GCC ATC AGA 
AGC AGT GTT GA-3’ for ABL1. B2M and 
HPRT1 were used for normalization. 
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11. Statistical analyses 
Student’s t-test was used for statistical 
analysis in HUVEC tube formation and 
DNA microarray experiments. The Mann-
Whitney U test was used in HUVEC tube 
formation and peptide binding experiments. 
Pearson’s chi-square (χ2) test was used to 
evaluate the correlation of gene expression 
changes between different studies. P-values 
< 0.05 were considered significant. 
12. Ethics 
The isolation of HUVECs and the use of 
human seminal fluid for purification of PSA 
were approved by the Institutional Review 
Board of Helsinki University Central 
Hospital.  
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RESULTS 
1. Characterization of PSA isoforms (I) 
To analyze the glycosylation and internal 
cleavages of PSA isoforms in seminal fluid, 
PSA was purified by immunoaffinity 
chromatography and further separated by 
anion-exchange chromatography into six 
different isoforms: PSA-A’, -A, -B, -C, -D 
and -E (Zhang et al. 1995, Wu et al. 2004a) 
(Figure 6A). When analyzed by mass 
spectrometry, the masses of the isoforms 
varied from 26808.9 to 28448.1 Da (Table 1 
in publication I). These masses and the 
masses of reduced and alkylated PSA 
isoforms and their fragments were used to 
calculate the theoretical composition of the 
isoforms, differences caused by peptide 
backbone cleavages, amino acid deletions 
and glycosylation.  
Isoforms PSA-A’, -A and -B were found 
to be intact. They represented full-length 
PSA and differed only in their glycan 
structure. The glycans were determined on 
the basis of the mass of the peptide moieties 
of   PSA   and   known   naturally   occurring  
 
 
 
 
Figure 6. A) Purification of PSA isoforms by anion-exchange chromatography. PSA was eluted with 0 - 0.3 M 
gradient of NaCl. PSA and protein concentrations were measured in the fractions by immunoassay (- ♦ -) and 
absorbance at 280 nm (—), respectively. Fractions of different PSA isoforms that were selected for MS and cell 
culture studies are shown with black boxes. B) The major proposed carbohydrate structures of PSA-A’, - A and 
- B. The masses of the PSA isoforms and the relative abundance of the glycans in each isoform are shown in 
parentheses. C) The proteolytic activity of PSA isoforms (0.1 µM) in the cell culture medium and their effect on 
HUVEC tube formation. Tube area is shown as percentage of the proPSA control (mean ± SE, * p < 0.001). A 
smaller area reflects a stronger antiangiogenic effect (n = 6 for all, except for mAb inhibition n = 4). 
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carbohydrates. In PSA-A’ the glycan 
contained high mannose structures without 
sialic acids, in PSA-A the major form was a 
hybrid-type glycan having one antenna with 
sialic acid, while in PSA-B the major form 
was a biantennary glycan of complex-type 
having two sialic acids, one in each antenna 
(Figure 6B). PSA-A’, -A and -B were shown 
to be enzymatically active isoforms, while 
PSA-C, -D and -E showed only weak, if any, 
activity as measured with the fluorogenic 
PSA substrate in the HUVEC cell culture 
medium (Figure 6C).  
PSA-C, -D and -E were internally 
cleaved and had a glycan structure similar to 
that of PSA-B. The cleavage sites, located 
between Arg85 and Phe86, Lys145 and 
Lys146, and Lys182 and Ser183 (numbering 
according to active PSA without propeptide), 
have been reported previously (Watt et al. 
1986; Zhang et al. 1995) (Figure 7). 
Previously unidentified cleavage sites were 
found between Asp84 and Arg85, Gly121 
and Pro122, Gly140 and/or Phe141 and/or 
Leu142, and Gly181 and Lys182. Due to the 
internal cleavages, isoforms PSA-D and -E 
lacked one or more amino acids. The 
enzymatically active isoform, PSA-B, was 
used in all further experiments and is 
hereinafter referred to as PSA. 
 
2. Proteolytic activity of PSA 
The enzymatic activity of PSA was 
measured with two small peptide substrates 
(Table 3). 
 
 
 
 
Figure 7. PSA sequence and the internal cleavage sites (shown with arrow heads). The amino acids forming the 
active site are shown in red, the S1 of the specificity pocket is in blue and marked with an asterisk, Asn45 
containing an N-linked carbohydrate is in green, the propeptide and the kallikrein loop are shown in yellow and 
the disulfide bridges with dashed lines in red (Menez et al. 2008). Numbering of the amino acids is according to 
active PSA without propeptide.  
 
 
 
Table 3. Enzyme kinetics of PSA with small peptide substrates.  
 
Km 
(mM) 
kcat 
(s-1) 
kcat / Km 
(s-1M-1) 
Chromogenic substratea 5.72 ± 1.53 0.75 ± 0.07 133.4 ± 24.6 
Fluorogenic substrateb 1.58 ± 0.04 0.19 ± 0.09 122.0 ± 59.4 
 
The values are mean ± SD of two experiments. 
a S-2586, MeO-Suc-Arg-Pro-Tyr-pNA·HCl  
b 4-morpholinecarbonyl-HSSKLQ-AMC 
propeptide
kallikrein loop
1 11 21 31
51 61 71 8141
101 111 121 13191
151 161 171 181141
201 211 221 231191
*
APLILSR IVGGWECEKH SQPWQVLVAS RGRAVCGGVL VHPQWVLTAA 
HCIRNKSVIL LGRHSLFHPE DTGQVFQVSH SFPHPLYDMS LLKNRFLRPG
DDSSHDLMLL RLSEPAELTD AVKVMDLPTQ EPALGTTCYA SGWGSIEPEE
FLTPKKLQCV DLHVISNDVC AQVHPQKVTK FMLCAGRWTG GKSTCSGDSG 
GPLVCNGVLQ GITSWGSEPC ALPERPSLYT KVVHYRKWIK DTIVANP 
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2.1 Identification of nidogen-1 as a PSA 
substrate (V) 
To identify ECM-derived protein substrates 
for PSA, the protein fragments resulting 
from the incubation of PSA with the 
Matrigel basement membrane preparation 
were visualized by SDS-PAGE and silver 
staining, and subsequently analyzed by MS. 
Nidogen-1 was identified by MS in the 55 
and 90 kDa fragments of Matrigel cleaved 
by PSA and in the 110 and 140 kDa bands of 
Matrigel not treated with PSA (Figure 8). 
These bands were also detected by the 
nidogen-1 antibody in Western blotting and 
PSA was separately shown to cleave human 
recombinant nidogen-1. 
N-terminal sequencing of the two 
fragments (55 and 85 kDa), resulting from 
the incubation of human recombinant 
nidogen-1 with PSA, revealed that both 
fragments had the same N-terminal 
sequence. Thus, the cleavage site 
GVVF380 ↓ SYNTD (numbering according 
to the UniProt sequence P14543) was 
identified for both. 
 
 
 
 
Figure 8. PSA cleaves nidogen-1 in Matrigel. Matrigel 
(protein concentration 250 µg/ml) was incubated 
with PSA (200 µg/ml, 7.1 µM) at 37 °C for 48 h and 
the silver-stained protein bands were analyzed by 
MS. Nidogen-1 was identified in the protein bands of 
Matrigel not treated with PSA (arrows, left lane) and 
in the fragments resulting from treatment with PSA 
(arrows, right lane). 
 
2.2 Degradation of protein substrates by 
PSA (V) 
The efficiency of the proteolytic activity of 
PSA was studied using different protein 
substrates: semenogelins I and II, 
fibronectin, galectin-3, IGFBP-3, nidogen-1 
and plasminogen. Semenogelins, the 
proposed physiological substrates of PSA, 
were cleaved most effectively. Analysis of 
the full-length protein bands in silver-stained 
gels showed that 50% of intact semenogelin 
I and II was cleaved after 11 min and 80 min 
incubation with PSA, respectively, while for 
fibronectin this took 17 h and for IGFBP-3, 
galectin-3 and nidogen-1 more than 20 h 
(Figure 9 and Figure 3A in V). PSA did not 
cleave plasminogen, even when different 
batches of purified PSA or plasminogen 
preparations from different manufacturers 
were used (Figure 3B in V). MMP-3 which 
was used as a control did cleave 
plasminogen. 
To ensure that the proteolytic activity 
resulted only from PSA activity, i.e., that the 
PSA preparation was not contaminated by 
other proteases, a monoclonal antibody 
mAb 5C7 that inhibits the proteolytic 
activity of PSA was shown to inhibit the 
cleavage of the protein substrates studied.  
 
3. Stimulators and inhibitors of PSA 
activity  
Peptides that stimulate and small molecule 
compounds that inhibit the proteolytic 
activity of PSA were used to further 
characterize the antiangiogenic (see 4. 
Antiangiogenic activity of PSA) and 
proteolytic activities of PSA. 
 
3.1 PSA-stimulating peptides (V) 
Peptides B2 and C4 identified by phage 
display bind to PSA and stimulate its activity 
(Wu et al. 2000). The effect of these peptides 
on the enzymatic activity of PSA was 
characterized using a chromogenic and a 
fluorogenic peptide substrate. Peptide C4 
was shown to stimulate the activity of PSA 
more efficiently than B2 toward both peptide 
substrates (Figure 10).  While C4 stimulated 
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Figure 9. Proteolytic cleavage of semenogelins and nidogen-1 by PSA (SDS-PAGE and silver staining). Protein 
substrates (1 µM each, except 0.5 µM semenogelin I) were incubated with 0.2 µM PSA at 37 °C for 22 h. Time 
points at which ~ 50% of the proteins were cleaved are indicated. 
 
 
 
 
 
 
Figure 10. Peptides stimulate PSA activity toward A) a chromogenic peptide substrate (n = 2, mean ± SD) and B) 
a fluorogenic peptide substrate (n = 3, mean ± SD). Peptide C4 stimulated the activity of PSA more efficiently 
than peptide B2-NH2 toward both substrates. Dashed lines (red) indicate the activity of PSA without peptide 
stimulation. 
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PSA activity six- to eight-fold [i.e., 610 ± 
8% and 785 ± 7% (mean ± SD), with fluoro-
genic and chromogenic substrates, respec-
tively], B2-NH2 caused a four-fold increase 
in PSA activity (i.e., 391 ± 11% and 400 ± 
14%, respectively). B2 was as effective as 
B2-NH2 and PSA activity was not stimulated 
by a B2-NH2-control peptide (Figure 10).  
The effect of peptides on the proteolytic 
activity of PSA was also studied with several 
protein substrates. Both peptides B2 and C4 
enhanced the activity of PSA toward 
semenogelins I and II, fibronectin, galectin-
3, IGFBP-3 and nidogen-1 (Figure 11 and 
Figure 4A in V). However, the efficiency of 
the peptides differed from that observed with 
small peptide substrates, as peptide B2 
stimulated PSA activity more effectively 
than C4 toward the protein substrates. IFMA 
detecting only full-length IGFBP-3 showed 
that the level of intact IGFBP-3 was 
decreased to 50% after 22 h incubation with 
PSA. Both peptides further decreased the 
amount of intact IGFBP-3 by enhancing the 
proteolytic activity of PSA, B2 being more 
effective than C4 (Figure 11). 
Surface plasmon resonance was used to 
study the binding kinetics and affinity of the 
PSA-stimulating peptides. All of them were 
found to bind to PSA, except for the inactive 
B2-NH2-control peptide (Figure S1 in V). 
The binding affinity, i.e., the equilibrium 
dissociation constant KD, was determined 
from the equilibrium plot that describes the 
binding (resonance units, RU) as a function 
of peptide concentration. Peptide B2 
(KD = 73.6 ± 20.3 µM, mean ± SD) and B2-
NH2 (KD = 56.5 ± 5.3 µM) were shown to 
bind more strongly to PSA than peptide C4 
(KD = 197.8 ± 30.5 µM) (p = 0.034 and 
p = 0.021, respectively). The binding affinity 
between B2 and B2-NH2 was not statistically 
significant (p = 0.29). 
 
 
 
 
 
 
Figure 11. Peptide B2 stimulated the proteolytic activity of PSA toward IGFBP-3 more strongly than C4 as 
detected by SDS-PAGE and silver staining, and by an IFMA recognizing intact but not cleaved IGFBP-3 (n = 2, 
mean ± SD).  
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3.2 Small molecule inhibitors of PSA (III) 
Screening of a library containing almost 
50,000 small drug-like compounds resulted 
in identification of two compounds (A1 and 
B1) that inhibited the activity of PSA in a 
dose-dependent fashion. Compounds similar 
to these, but with small structural changes, 
were tested further. Three compounds that 
inhibited PSA activity most effectively (A1, 
B1 and B3) were studied for their biological 
activity in the HUVEC tube formation assay 
(see 4. Antiangiogenic activity of PSA).  
 
4. Antiangiogenic activity of PSA (I-III, 
V) 
The antiangiogenic activity of PSA was 
studied in a HUVEC tube formation assay 
(Kubota et al. 1988; Arnaoutova and 
Kleinman 2010). In this model HUVECs 
grown on top of Matrigel differentiate 
spontaneously into tubular network 
structures during 16 - 20 h of incubation. 
PSA was shown to inhibit HUVEC tube 
formation in a dose-dependent fashion and 
this antiangiogenic activity was statistically 
significant at 0.1 µM and higher concentra-
tions (I) (Figure 12).  
The antiangiogenic activity of PSA was 
shown to be dependent on its enzymatic 
activity (I) (Figure 6C). The enzymatically 
inactive precursor form of PSA, proPSA, did 
not affect tube formation as compared to the 
buffer control. Contrary to proPSA, the 
enzymatically active PSA isoforms A and B 
(0.1 µM) significantly inhibited HUVEC 
tube formation by decreasing the tube area to 
52.7 ± 5.1% and 58.8 ± 2.9% (mean ± SE, 
p < 0.001 for both) of that of the proPSA 
control, respectively. Internally cleaved 
forms PSA-C, -D and -E, which showed only 
weak enzymatic activity, did not have any 
significant effect on tube formation (Figure 
6C). A monoclonal antibody mAb 5C7 and 
two small molecule PSA-inhibitors blocked 
the antiangiogenic effect of active PSA (I, 
III) (Figures 6C and 13) and peptides that 
stimulate the activity of PSA enhanced this 
effect (II) (Figures 13 and 14). Chymotryp-
sin (0.1 µM) did not significantly affect tube 
formation (88 ± 10% of PBS-control, n = 3, 
p = 0.35) (I). 
Originally, we quantified HUVEC tube 
formation by measuring the area covered by 
the tubular network (I and III). Later, 
quantification was refined  to  better  analyze  
 
 
 
 
Figure 12. Effect of PSA (0.01 - 1 µM) on HUVEC tube formation. Cells were stained with TexasRed-X Phalloidin 
and DAPI. Scale bar, 100 µm. 
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Figure 13. Effect of PSA-stimulating peptides (100 µM), in serum-containing (A) and in serum-free (B) medium, 
and PSA-inhibitors (80 µM) (C) on the antiangiogenic activity of PSA in HUVEC tube formation assay. The 
angiogenesis index is shown as the percentage of the control (mean ± SE, * p < 0.05). PSA activity, measured in 
the medium before (0 h) and after (16 or 18 h) the incubation, is shown as percentage of PSA at the beginning 
of the experiment (mean ± SE, p-values were not determined). Panel A: PSA (0.1 µM), n = 11, except n = 4 for 
proPSA and PSA + mAb. Panel B: PSA (0.1 µM), n = 6, except n = 4 for C4, B2 and PSA + B2-control. Panel C: PSA 
(0.3 µM), n = 4. 
 
 
 
 
Figure 14. Peptide C4 enhanced the antiangiogenic activity of PSA in HUVEC tube formation assay. A) Buffer 
control, B) 100 µM C4, C) 0.1 µM PSA, and D) 0.1 µM PSA + 100 µM C4 in serum-free medium. Tube formation 
was quantified by angiogenesis index, i.e., the tube area (red outlines in A) multiplied by the number of closed 
structures in the tubular network (dots). Scale bar, 300 µm. 
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the effect of various treatments on the 
angiogenic potential of the cells. This was 
achieved by counting all closed network 
structures and by multiplying this number 
with the tube area, which yielded a value 
called angiogenesis index (II) (Figure 14). 
Based on the angiogenesis index, 
0.1 µM active PSA-B inhibited tube 
formation by 47.4 ± 2.8% (mean ± SE) as 
compared to the buffer control (p < 0.001) in 
a serum-containing medium (II) (Figure 
13A). Peptide C4 enhanced the antiangio-
genic effect of PSA by decreasing the 
angiogenesis index to 33.5 ± 3.1% of the 
control (p < 0.001), i.e., together with PSA 
peptide C4 caused a further 29.4% reduction 
in the angiogenesis index as compared to that 
of PSA (p = 0.003) (Figure 13A). 
In serum-free conditions PSA reduced 
the angiogenesis index to 54.3 ± 4.3% of the 
corresponding buffer control (p = 0.004) (II) 
(Figure 13B). Both peptides B2 and C4 
stimulated the antiangiogenic effect of PSA 
to a similar extent by decreasing the 
angiogenesis index to 37.2 ± 4.8% and 
37.5 ± 4.2% of the control, respectively 
(p = 0.004 for both), i.e., caused a 31.5% 
(p = 0.016) and 30.9% (p = 0.037) reduction, 
respectively, as compared to PSA alone 
(Figure 13B).  
In a serum-containing medium stimula-
tion of PSA activity by C4 was lost during 
incubation, while it was better retained in a 
serum-free medium (II) (Figure 13A and B). 
There was, however, no significant differ-
ence in stimulation of the antiangiogenic 
activity of PSA by the peptides in serum-
containing versus serum-free media. Based 
on a standard curve for different PSA 
concentrations and the corresponding angio-
genesis index, 0.1 µM PSA and 100 µM of 
either peptide caused a similar effect in the 
tube formation assay as 0.24 µM PSA. Thus, 
the peptides stimulated the antiangiogenic 
activity of PSA 2.4-fold.  
Two of the compounds that inhibited 
PSA activity (B1 and B3) were tolerated well 
in the HUVEC tube formation assay, while 
A1 was found to be toxic for the cells (III). 
In the original study, the tube area was used 
for quantification, but to compare the data 
with that of the peptides the angiogenesis 
index was determined (Figure 13C). Here, 
0.3 µM PSA inhibited tube formation by 
decreasing the angiogenesis index to 
25.3 ± 4.3% (mean ± SE) as compared to the 
buffer control (p = 0.014) (Figure 13C). 
Compounds B1 and B3 significantly inhib-
ited the antiangiogenic activity of PSA 
(p = 0.021 for both as compared to PSA), 
their angiogenesis index being 80.0 ± 15.3% 
(p = 0.219) and 96.3 ± 7.1% (p = 0.508) of 
that of the buffer control, respectively 
(Figure 13C).  
To characterize the mechanism of the 
antiangiogenic activity of PSA, we studied 
the effect of conditioned medium that was 
collected from PSA-treated (0.5 µM) and 
control HUVECs on cells plated freshly on 
Matrigel. The angiogenesis index of PSA-
treated conditioned medium without the 
antibody inhibition was 28.8 ± 7.5% of the 
buffer control (p = 0.014). When the activity 
of PSA in the conditioned medium was 
blocked by mAb 5C7 (with the inhibition 
confirmed in medium samples by the 
fluorogenic peptide substrate) and HUVECs 
were grown in this medium overnight, 
inhibition of HUVEC tube formation was 
still evident (59.6 ± 15.1% of the buffer 
control, p = 0.014) (Mattsson et al. 
unpublished data) (Figure 15). The fresh 
medium, in which the activity of PSA was 
inhibited by the antibody, lacked antiangio-
genic activity. The antiangiogenic effect was 
observed only in conditioned medium 
collected from HUVECs grown with PSA on 
Matrigel, but not in the medium collected 
from HUVECs grown with PSA on plastic 
surface, nor in the medium in which PSA 
was incubated on Matrigel without the cells 
(Mattsson et al. unpublished data).  
Since these unpublished results suggest 
that PSA may generate proteolytic fragments 
or other factors into the cell culture medium 
that mediate its antiangiogenic effect, we 
tested the fragments of the two angiogenesis-
related protein substrates of PSA, nidogen-1 
and galectin-3, and their full-length forms in 
the tube formation assay (V).  None  of  these 
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Figure 15. Antiangiogenic effect of the conditioned medium collected from PSA-treated HUVECs grown on 
Matrigel after inhibition of PSA activity by mAb 5C7 (Mattsson et al. unpublished data). The angiogenesis index 
(mean ± SE) is shown in the fresh and conditioned medium from PSA-treated and control HUVECs, with and 
without subsequent inhibition of PSA activity by the mAb. Antiangiogenic activity was found in the conditioned 
medium containing 0.5 µM PSA inhibited by 1 µM mAb, while the fresh medium containing the same 
concentrations of PSA and antibody lacked effect. Data from four independent assays with duplicates (n = 4, 
* p < 0.05).  
 
 
 
were found to inhibit angiogenesis in the 
HUVEC tube formation model (Figure 5 in 
V). Measurement of the angiogenesis 
inhibitors angiostatin and endostatin in the 
cell culture medium, collected from the 
HUVEC tube formation assay, showed that 
there was no detectable concentrations of 
angiostatin present in either PSA-treated or 
control medium (minimum sensitivity of the 
assay was < 20 ng/ml) (Mattsson et al. 
unpublished data). Low levels of endostatin 
were detected both in PSA-treated and 
control media (0.64 ± 0.11 ng/ml and 1.7 ± 
0.2 ng/ml, respectively, p = 0.02, n = 3).  
PSA did not affect the viability of 
LNCaP cells grown on Matrigel (108 ± 8%, 
n = 2, p = 0.49), nor the proliferation or the 
viability of HUVECs grown in monolayer on 
a plastic surface (100 ± 2% and 102 ± 2% of 
control, n = 3 and n = 2, respectively, p ≥ 0.5 
for both) (I).  
 
5. PSA-induced changes in HUVEC gene 
expression (IV) 
DNA microarray was performed to identify 
PSA-induced changes in gene expression of 
HUVECs during tube formation (n = 3). Of 
altogether 41,000 probes in the microarray, 
PSA altered the expression of 311 genes with 
a > 1.5-fold difference and p < 0.05 as 
compared to the untreated control, with 171 
of the genes being up-regulated and 140 
down-regulated (Table 1 in IV, shows the 20 
most up-regulated and the 20 most down-
regulated genes). The gene expression 
changes were found to be enriched in several 
biochemical pathways and gene ontology 
categories in the KEGG and GO databases. 
For a preliminary validation of the DNA 
microarray data, five genes, two that were 
up-regulated by PSA (HES7 and BMP8A) 
and three that were down-regulated (ABL1,  
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CYR61 and PGF), were also analyzed by 
quantitative RT-PCR (n = 7 for each gene). 
The expression of these genes, except for 
PGF, showed a similar trend in RT-PCR as 
in the microarray, but the difference in the 
gene expression in RT-PCR was statistically 
significant only for BMP8A (p = 0.027). 
When the microarray data was 
compared to similar data from other studies, 
the PSA-induced changes in HUVEC gene 
expression were found to be opposite to 
those described previously to occur during 
normal endothelial cell tubulogenesis 
(p = 2.4 x 10-5) (Glesne et al. 2006) (Figure 
16). There was, however, no correlation 
between PSA-induced changes and changes 
associated with endothelial cell proliferation 
(Glesne et al. 2006), those induced by 
growth factors VEGF and PlGF (Schoenfeld 
et al. 2004) or by the angiogenesis inhibitors, 
angiostatin and endostatin (Cline et al. 
2002).  
 
 
 
 
 
Figure 16. Comparison of PSA-induced gene expression changes with those in other studies. The 200 most up-
regulated and the 200 most down-regulated genes in the present study with ≥ 1.5-fold up-regulation and down-
regulation and p < 0.05 were chosen for the comparison. PSA-induced changes in HUVEC gene expression were 
opposite to those associated with normal tubulogenesis (Glesne et al. 2006), but they did not correlate with 
changes associated with endothelial cell proliferation or those induced by angiostatin or endostatin (Cline et al. 
2002). The number of genes, which were up-regulated (up) or down-regulated (down) in the present study (PSA) 
and/or in the other studies, and the corresponding Pearson’s chi-square p-values are shown.  
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DISCUSSION 
In addition to its major physiological 
function, the liquefaction of semen by 
proteolytic cleavage of semenogelins (Lilja 
1985), PSA may have functions related to 
prostate cancer development. Several studies 
have shown that PSA degrades various 
proteins in vitro, some of which are involved 
in cancer (see Table 1). Also, functions 
independent of its proteolytic activity have 
been described (Sun et al. 2001; Fortier et al. 
2003; Niu et al. 2008; Chadha et al. 2011). It 
is not known which of these functions are of 
biological relevance. So far, there is no 
consensus regarding the functional role of 
PSA in cancer and PSA may increase as well 
as inhibit tumor growth.  
In this thesis work, the antiangiogenic 
and proteolytic activities of PSA were 
characterized. The nature of the antiangio-
genic activity of PSA was evaluated in vitro 
and the proteolytic activity of PSA was 
studied with several peptide and protein 
substrates. Stimulators and inhibitors of PSA 
activity were studied with respect to their 
effect on the antiangiogenic and proteolytic 
activity of PSA. The proteolytic activity was 
shown to be essential for the antiangiogenic 
activity of PSA. Comparisons among several 
protein substrates showed that PSA cleaved 
semenogelins most efficiently. However, 
other substrates may be of importance with 
respect to prostate cancer, since there are 
high concentrations of PSA in the tumor 
microenvironment.  
Characterization of the antiangiogenic 
and proteolytic properties of PSA increases 
our understanding of the biological function 
of PSA. Knowledge about the molecular 
mechanisms of the antiangiogenic activity of 
PSA would open new avenues for treating 
prostate cancer. If PSA does affect prostate 
cancer progression, stimulation or inhibition 
of its activity could be used to control 
prostate cancer growth.  
 
 
 
1. Characterization of internal cleavage 
sites and glycosylation of PSA isoforms (I) 
Enzymatically active intact PSA comprises 
~ 65% of the PSA in seminal plasma, while 
~ 35% of the PSA is internally cleaved and 
therefore inactive (Lilja 1985; Watt et al. 
1986; Christensson et al. 1990; Zhang et al. 
1995). The internal cleavage sites and carbo-
hydrate structure of enzymatically active and 
inactive PSA isoforms were determined in 
the present study. The term isoform refers 
here to differentially glycosylated and/or 
cleaved forms of the full-length PSA and not 
to alternative splicing variants.  
The internally cleaved forms PSA-C, -D 
and -E represent a mixture of differently 
cleaved forms, with the previously identified 
major cleavage sites between amino acids 
Arg85 and Phe86, Lys145 and Lys146, and 
Lys182 and Ser183 (numbering according to 
active PSA without propeptide) (Watt et al. 
1986; Zhang et al. 1995). We observed 
further truncation of amino acids adjacent to 
these sites and other previously unidentified 
cleavage sites. These sites are between 
amino acids Gly121 and Pro122, and Gly140 
and/or Phe141 and/or Leu142. Most of the 
cleavage sites are located on the surface of 
PSA, except the site between Lys182 and 
Ser183, which is located at the bottom of the 
specificity pocket (Menez et al. 2008). In 
addition, the cleavage sites between Asp84 
and Phe86 are located in the kallikrein loop, 
while those between Gly140 and Leu142, 
and Lys145 and Lys146 are in the region 
corresponding to the autolysis loop of 
chymotrypsin (Bodi et al. 2001). The active 
isoforms did not contain any internal 
cleavages, and thus, different cleavages 
obviously lead to inactivation of the 
proteolytic activity of PSA. It is not known 
whether this inactivation serves as a 
mechanism that regulates PSA activity. It is 
very likely that PSA is proteolytically 
cleaved already in the prostate, since the 
proportion of different PSA isoforms in 
prostate tissue culture medium is very 
similar to that in seminal fluid (Zhang et al. 
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1995; Zhu et al. 2013). However, more 
extensive proteolytic cleavage of PSA may 
take place in the seminal fluid. The 
measurement of internally cleaved and 
uncleaved forms of PSA may be clinically 
useful (Peltola et al. 2011).  
The active isoforms PSA-A’, -A and -B 
display differences in their glycosylation 
patterns. The main glycan structure of PSA 
found in this study was identical to that 
reported earlier (Belanger et al. 1995; 
Peracaula et al. 2003; Ohyama et al. 2004), 
but glycan structures of the minor PSA 
isoforms have not been previously character-
ized. A structural diversity of glycans is 
typical for mammalian glycoproteins and 
altered glycosylation is also common in 
cancer (Ohtsubo and Marth 2006; Moremen 
et al. 2012). The differences in sialylation of 
PSA-A and -B do not significantly affect 
their activity, but may have other 
consequences, because sialylation plays a 
significant role in protein interactions and 
may also affect the half-life of the proteins 
(Varki 2008). Our results do not indicate 
whether the differences in sialylation of PSA 
isoforms arise already in the prostate, e.g., 
during glycan synthesis, or later in the 
seminal fluid. The latter is possible since 
seminal fluid contains sialidase activity 
(Bostrom and Ockerman 1971; du Toit et al. 
1998) which could cause loss of terminal 
sialic acid moities. Indeed, it has been shown 
that although the proportion of different PSA 
isoforms secreted from prostate tissue is 
otherwise similar to that recorded for the 
seminal fluid, PSA-A’ and PSA-A have not 
been identified in the former (Zhu et al. 
2013).  
Changes in glycosylation, e.g., 
increased size and branching of N-linked 
glycans or overproduction of certain 
terminal glycans, may occur in cancer cells 
(Peracaula et al. 2003; Dube and Bertozzi 
2005; Meany and Chan 2011). Altered 
glycosylation of PSA has been reported in 
prostate cancer (Meany and Chan 2011; 
Gilgunn et al. 2013), since specific altera-
tions in fucosylation and sialylation of PSA 
occur in prostate cancer as compared to PSA 
in healthy men (Kyselova et al. 2007) and 
patients with BPH (Ohyama et al. 2004; 
Sarrats et al. 2010; Saldova et al. 2011). 
Increased knowledge about the differences 
in PSA glycosylation between benign and 
malignant prostate could improve the 
diagnosis of prostate cancer.  
 
2. Proteolytic activity of PSA toward 
protein substrates (V) 
The physiological function of PSA is 
proteolytic cleavage of semenogelins, which 
liquefies the seminal clot formed after 
ejaculation and enables the spermatozoa to 
move freely toward the fertilization site 
(Lilja 1985). As the proteolytic activity of 
PSA may be relevant also in prostate cancer 
development, we studied the ability of PSA 
to cleave different protein substrates. Apart 
from nidogen-1, which we identified as a 
novel PSA substrate, PSA has previously 
been shown to cleave the other substrates 
which we studied (Table 1 and Figure 17). 
However, due to variation in PSA 
preparations and the experimental conditions 
in the previous studies, a comparison of the 
efficiency of PSA to cleave these substrates 
has not been possible.  
Our results showed that PSA cleaves 
semenogelins much more efficiently than 
other protein substrates. The time during 
which 50% of semenogelin I was degraded, 
11 min, was in keeping with that observed in 
an earlier study (Malm et al. 2000). Under 
physiological conditions the cleavage of 
semenogelins in the seminal fluid is still 
much more rapid (Emami and Diamandis 
2012), which may be explained by the 
presence of other KLKs that also degrade 
semenogelins, e.g., KLK2, 5 and 14 
(Deperthes et al. 1996; Lövgren et al. 1999b; 
Michael et al. 2006; Emami et al. 2008). The 
other protein substrates we studied were 
degraded with a much lower efficiency than 
semenogelins and 50% cleavage was 
observed only after overnight incubation 
with PSA. This raises the question of 
whether these substrates are, in fact, of 
consequence  for  the function(s)  of  PSA  in 
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Figure 17. Potential functions for PSA in normal physiology and prostate cancer. 
 
 
vivo. On the other hand, the PSA levels in the 
prostate are extremely high, and thus, even a 
weak activity toward some substrates may be 
important. The main criterion for a 
physiologically or biologically relevant 
substrate is that it is present in vivo in the 
same cellular or extra-cellular compartment 
at the same time as the protease (Turk et al. 
2012). Thus, all substrates that are degraded 
in vitro may not be biologically relevant. 
Apart from the semenogelins, which are 
produced in the seminal vesicles (Lilja 
1985), the substrates selected for this study 
are present in the prostate (Thrasher et al. 
1996; Pacis et al. 2000; Uhlen et al. 2005; 
The Human Protein Atlas, version 12, 
www.proteinatlas.org, accessed April 2014) 
together with high concentrations of PSA 
and also during prostate cancer development. 
These substrates are thus reasonable candi-
dates as mediators of the cancer-related 
functions of PSA. The potential functions 
include stimulation of tumor growth by the 
release of active IGF-I by degradation of 
IGFBP-3 (Cohen et al. 1992; Cohen et al. 
1994), facilitation of invasion and metastatic 
dissemination via degradation of the ECM 
components fibronectin (Lilja et al. 1987; 
Webber et al. 1995) and nidogen-1 and 
regulation of the proinvasive and prolifera-
tive functions of galectin-3 (Wang et al. 
2009; Saraswati et al. 2011).  
Previously, it has been shown that PSA 
cleaves some unidentified proteins in the 
Matrigel basement membrane preparation 
(Ishii et al. 2004). We used mass 
spectrometry to identify one such protein, 
nidogen-1, which has not previously been 
documented as a substrate for PSA. 
Nidogen-1 is a basement membrane protein 
with binding sites for laminin, collagen type 
IV and a heparan sulfate proteoglycan, 
perlecan (Ries et al. 2001; Ho et al. 2008). 
The cleavage site for PSA in nidogen-1 is 
located between phenylalanine and serine 
(amino acid residues 380 and 381 according 
to the UniProt sequence P14543) between 
the globular domains G1 and G2 in the link 
region that is highly sensitive to proteolysis 
(Fox et al. 1991; Mayer et al. 1993). As the 
cleavage of nidogen-1 occurs just before 
domain G2, PSA releases domain G1 and 
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most of the link region. Unlike the G2 and 
G3 domains, domain G1 is not involved in 
binding to other basement membrane 
proteins except fibulin-2 (Mayer et al. 1993; 
Ries et al. 2001). Although nidogen-1 was 
thought to serve as a link between laminin 
and collagen networks in the basement 
membrane (Fox et al. 1991; Mayer et al. 
1993), it may not be essential for this linking 
function since deficiency of nidogen-1 
results in only mild effects in knockout mice 
(Murshed et al. 2000; Willem et al. 2002; 
Bader et al. 2005). Indeed, it has been 
recently shown that, although nidogen-1 
binds to both laminin and collagen networks, 
it is not responsible for direct linking of these 
networks, which is mediated by heparin 
sulfate proteoglycans (Behrens et al. 2012). 
However, nidogen-1 may have other 
functions, which may occur in the basement 
membranes of certain tissues or only at 
different developmental stages. For example, 
nidogen-1 has been associated with angio-
genesis: it is up-regulated in endothelial tip 
cells during blood vessel formation (del Toro 
et al. 2010). Also, the lack of nidogen-1 
expression in knockout mice has been 
associated with increased choroidal neovas-
cularization of the eye (Semkova et al. 
2014), while the cleavage of nidogen-1 has 
been connected to the tumor growth-sup-
pressive function of ADAMTS-1 (Martino-
Echarri et al. 2013). Although the ultimate 
biological significance of the cleavage of 
nidogen-1 by PSA is unclear, it may be 
relevant for cancer development.  
Despite the fact that the chymotrypsin-
like activity of PSA is low and its specificity 
is more restricted than that of chymotrypsin 
(the catalysis is more dependent on the 
precise amino acid sequence of the substrate) 
(Watt et al. 1986; Coombs et al. 1998; Menez 
et al. 2008), there is a large variation in the 
reported cleavage sites of PSA in different 
substrates. The most common amino acid 
residues after which PSA cleaves peptide 
bonds, e.g., in the semenogelins, are tyrosine 
and glutamine (Coombs et al. 1998; Malm et 
al. 2000; LeBeau et al. 2010). We used N-
terminal sequencing and found that PSA 
cleaves nidogen-1 between the amino acid 
residues phenylalanine and serine. Although 
chymotrypsin cleaves efficiently and fre-
quently the peptide bond between these 
amino acid residues, the MEROPS database 
lists only two such cases, the cleavage of 
PTHrP (Cramer et al. 1996; Iwamura et al. 
1996) and a synthetic peptide substrate (Watt 
et al. 1986), where phenylalanine is located 
at the P1 position of the cleavage site of PSA. 
In contrast, serine is by far the most common 
amino acid residue at the P1’ position 
(MEROPS identifier for PSA S01.162; 
Rawlings et al. 2012). The cleavage site in 
nidogen-1 does not correspond to any of the 
34 cleavage sites reported for the 
semenogelins (Malm et al. 2000). When the 
subsite preferences for recombinant non-
glycosylated PSA at the nonprime side of the 
cleavage site were studied using a positional 
scanning combinatorial library of tetra-
peptide substrates, PSA turned out to prefer 
hydrophobic (Met, Ala, Tyr, Leu or Phe) but 
also polar (Arg, Lys) residues at the P1 
position (Debela et al. 2006). Thus, the 
nidogen-1 cleavage site fits well into this 
cleavage profile of PSA. However, 
methionine has not been among the most 
preferred P1 amino acid residues reported in 
other studies.  
Seminal fluid contains several highly 
active proteases, including trypsin and 
KLK2 (the major trypsin-like KLK in the 
seminal fluid) (Lövgren et al. 1999a; Paju et 
al. 2000). It is possible that some PSA 
preparations may be contaminated by minute 
amounts of these proteases and that this 
gives false results in proteolytic activity 
studies of PSA and its substrates (Frenette et 
al. 1998). Indeed, several commercially 
available PSA preparations have been found 
to contain trypsin-like enzymatic activity 
(Manning et al. 2012). Although the levels of 
KLK2 and trypsin in seminal fluid are much 
lower than those of PSA (Lövgren et al. 
1999a; Paju et al. 2000), even a minor 
contamination may be significant, since the 
activities of KLK2 and trypsin, including 
their ability to degrade IGFBP-3, are at least 
100-fold higher than the activity of PSA 
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toward most substrates (Christensson et al. 
1990; Mikolajczyk et al. 1997b; Koistinen et 
al. 2002). Thus, some of the reported PSA 
substrates might not actually have been 
cleaved by PSA at all, but rather their 
cleavage has been mediated by other 
proteases present as contaminants in the PSA 
preparations used in the experiments. The 
PSA used in the present study was highly 
purified and did not contain any detectable 
KLK2 or trypsin activity, as measured by 
chromogenic substrates (Zhang et al. 1995 
and Mattsson et al. unpublished data). As a 
further control, the proteolytic activity of 
PSA toward the studied protein substrates 
was shown to be blocked by a PSA-specific 
monoclonal antibody (mAb 5C7).  
 
2.1 Stimulators and inhibitors of the 
enzymatic activity of PSA (III, V) 
PSA is an intriguing target for treatment and 
imaging of prostate cancer due to the high 
prostate-specific expression and the potential 
role of PSA in prostate cancer development 
(Ulmert et al. 2012; Mavridis et al. 2014). 
Molecules that stimulate or inhibit the 
enzymatic activity of PSA could be useful 
targets for drug development. We identified 
small molecule PSA-inhibitors by high-
throughput screening of small molecule 
libraries, but we did not identify any 
stimulators (III). The inhibitory compounds 
belonged to two structural families, and of 
these the triazole-containing compounds 
have not been identified as protease inhibi-
tors previously, while the benzoxazinone 
derivatives are known to inhibit several 
serine proteases, including chymotrypsin 
(Teshima et al. 1982). Molecular modelling 
studies imply that these inhibitors bind to the 
active site of PSA. 
Previously, phage display was used to 
identify peptides that specifically bind to 
PSA and stimulate its enzymatic activity 
(Wu et al. 2000). Peptides C4 and B2 were 
produced as fusion proteins with 
glutathione-S-transferase (GST) and were 
found to cause a 50% stimulation of PSA 
activity at 0.57 µM and 1.7 µM concentra-
tions, respectively, as measured with a 
chromogenic substrate (Wu et al. 2000). In 
the present study, the synthetic PSA-
stimulating peptide C4 was found to be more 
efficient than B2 or B2-NH2 in stimulating 
the enzymatic activity of PSA toward both 
chromogenic and fluorogenic peptide 
substrates (V). Peptides C4 and B2 also 
stimulated the activity of PSA toward several 
protein substrates, but contrary to the effect 
on small peptide substrates, peptide B2 was 
more efficient than C4. These differences 
may be explained by the size and structure of 
the substrates and the peptides. The peptides 
seem to bind near the active site of PSA and 
their binding may stabilize the kallikrein 
loop in an open conformation which would 
lead to increased proteolytic activity of PSA 
(Wu et al. 2000; Pakkala et al. 2004; 
Härkönen et al. 2011). It is possible that C4, 
when binding to PSA and stimulating its 
activity, may somewhat hinder the access of 
protein substrates to the active site, while the 
smaller peptide B2 does not have such an 
effect. 
When the interaction of the peptides 
with PSA was studied by SPR, the binding 
was found to be very fast but much weaker 
than with GST-fusion peptides (V). Both B2 
peptides bound more strongly to PSA than 
C4, while the opposite was true for the GST-
peptides (Wu et al. 2000). The differences in 
binding characteristics between synthetic 
peptides and GST-fusion peptides may be 
explained by the presence of multimeric 
GST-peptides that are likely to have a higher 
avidity than the monomeric peptides (Wu et 
al. 2000). 
 
3. Antiangiogenic activity of PSA (I-V) 
Previously, PSA has been shown to inhibit 
proliferation, migration, invasion and tube 
formation of HUVECs, as well as prolifera-
tion of human microvascular dermal 
endothelial cells and bovine adrenal 
capillary endothelial cells in vitro (Fortier et 
al. 1999). Furthermore, PSA inhibited blood 
vessel growth in vivo in a Matrigel plug 
model, either when administered subcutane-
ously (Fortier et al. 2003) or inside Matrigel 
plug (Hekim et al. unpublished data). The 
61 
 
molecular mechanism of the antiangiogenic 
activity of PSA is still unknown and it has 
even been unclear whether the proteolytic 
activity of PSA is needed for this activity 
(Fortier et al. 2003; Chadha et al. 2011).  
Although HUVECs represent endothe-
lial cells of large blood vessels and differ 
somewhat from the cells of tumor blood 
vessels, the HUVEC tube formation assay on 
Matrigel was chosen as a model for the 
present study, as it is a widely used in vitro 
assay for angiogenesis and is rapid, reliable 
and easy to perform (Arnaoutova and 
Kleinman 2010). It involves several steps of 
the angiogenic process, such as adhesion, 
migration and tube formation (Arnaoutova et 
al. 2009).  
The present study confirms that PSA 
exerts antiangiogenic activity in vitro in the 
HUVEC tube formation model, as deter-
mined by reduced formation of tubular 
networks (I-V). The antiangiogenic activity 
was specific for PSA, since chymotrypsin 
did not show this activity (I). Different 
enzymatically active and inactive forms of 
PSA were used to show that the proteolytic 
activity of PSA is essential for its 
antiangiogenic activity (I). Furthermore, 
inactive proPSA did not exert antiangiogenic 
activity, and inhibition of the enzymatic 
activity of PSA by a monoclonal antibody or 
small molecule inhibitors abolished the 
antiangiogenic effect (III), while PSA-
stimulating peptides enhanced it (II).  
Two peptides, C4 and B2, stimulated the 
proteolytic activity of PSA and also 
enhanced its antiangiogenic activity in the 
HUVEC tube formation model (II). The 
peptides were not toxic in cell culture 
conditions. The stimulating effect of the 
peptides was lost in a serum-containing 
medium during incubation, perhaps due to 
binding to albumin or due to proteolytic 
cleavage. However, there was no difference 
in stimulation of the antiangiogenic activity 
of PSA as compared to experiments with 
serum-free medium, in which the stimulatory 
effect was retained during the whole 
experiment.  
Among the three small molecule PSA-
inhibitors tested, two were not toxic in vitro 
(III). Both compounds belonged to the same 
structural family of triazole-containing 
compounds and were shown to effectively 
inhibit the antiangiogenic activity of PSA in 
the HUVEC tube formation model, even 
though the inhibition decreased during the 
incubation, i.e., PSA activity was recovered 
as measured by a chromogenic substrate.  
Taken together, PSA activity has to be 
present and its stimulation or inhibition has 
to occur in the early phase of tube formation, 
when assessed by the HUVEC tube 
formation model. Possibly the presence of 
active PSA at an early stage is sufficient to 
generate the antiangiogenic effect and at 
least this effect can no longer be generated 
after overnight incubation of HUVECs on 
Matrigel (Mattsson et al. unpublished data). 
Contrary to our results, some studies 
have suggested that the antiangiogenic 
activity of PSA is distinct from its 
proteolytic activity. In the landmark study, 
Fortier and coworkers showed that the 
antiangiogenic activity of PSA can be 
blocked by the protease inhibitor ACT 
(Fortier et al. 1999), but they later reported 
that a recombinant, proteolytically inactive 
variant of PSA with a single amino acid 
deletion in the N-terminus, exerts 
antiangiogenic activity both in vitro and in 
vivo (Fortier et al. 2003). Since all our results 
indicate unequivocally that proteolytic 
activity is required for the antiangiogenic 
activity of PSA, it is possible that the 
deletion in the N-terminus was not sufficient 
for total inhibition of the proteolytic activity 
of PSA or that this form of PSA retains its 
activity in experimental conditions. Also, 
PSA inactivated by Zn2+ was shown to 
inhibit angiogenesis in vitro (Chadha et al. 
2011). However, the Zn2+ concentration used 
(50 µM) was very low and, based on other 
studies and our results (not shown), it would 
not have been sufficient to totally inhibit 
1 µM PSA as reported (Malm et al. 2000; 
Chadha et al. 2011). We found that the 
concentration   of   Zn2+   (1 mM)  that   effect-
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tively inhibited 1 µM PSA, as measured with 
a chromogenic peptide substrate, was toxic 
for HUVECs (Mattsson et al. unpublished 
data). It is also possible that Zn2+ dissociates 
from PSA in cell culture conditions and that 
this releases active PSA, similar to what 
occurs in seminal fluid where Zn2+ bound to 
PSA is captured by semenogelins, leading to 
activation of PSA.  
The results of this thesis consistently 
show that the antiangiogenic activity of PSA 
is dependent on the proteolytic activity. To 
support this observation and to approach the 
molecular mechanism of the antiangiogenic 
effect of PSA, we performed an experiment 
in which conditioned medium was collected 
from PSA-treated and control HUVECs 
grown on top of Matrigel, i.e., using the same 
conditions as normally in the tube formation 
assay. In order to study the effect of possible 
degradation products generated by PSA or 
other factors induced by PSA, the 
conditioned medium was treated with a 
monoclonal antibody that blocked PSA 
activity. The inhibition of PSA activity by 
the mAb was confirmed by the measurement 
of PSA activity with a fluorogenic peptide 
substrate in conditioned medium samples. 
Although there was no more PSA activity 
present in the medium, we still recorded an 
antiangiogenic effect, albeit somewhat 
weaker than the original effect exerted by 
PSA, when this medium was applied to 
HUVECs grown on Matrigel (Mattsson et al. 
unpublished data). This observation fits well 
with the hypothesis that the antiangiogenic 
activity is mediated by a proteolytic 
fragment generated by PSA. However, it 
does not rule out the possibility that some 
other mechanism, e.g., gene expression 
changes, could mediate this activity. 
Although it was shown that PSA cleaves 
nidogen-1 in Matrigel, the antiangiogenic 
activity of PSA in the HUVEC tube 
formation assay is apparently not caused by 
proteolytic cleavage of nidogen-1. This was 
supported by an experiment in which gelled 
Matrigel was pretreated overnight with PSA 
in cell culture medium, followed by 
inhibition of PSA activity with mAb 5C7. 
The pretreatment of Matrigel with PSA did 
not inhibit tube formation of the HUVECs 
(Mattsson et al. unpublished data). Also, 
nidogen-1 or galectin-3, both of which have 
been associated with angiogenesis (Nangia-
Makker et al. 2000; del Toro et al. 2010), or 
their fragments generated by PSA, were not 
found to have any effect on tube formation in 
this assay (V). 
The molecular mechanism underlying 
the antiangiogenic effect of PSA is still 
unknown. Several studies have shown that 
many endogenous angiogenesis inhibitors 
are proteolytic fragments of various 
extracellular matrix or non-matrix proteins 
(reviewed in Nyberg et al. 2005; Ribatti 
2009). This being the case, PSA could exert 
its antiangiogenic function through degrada-
tion of one of these proteins. There is one 
study implying that the antiangiogenic effect 
of PSA could be mediated by the cleavage of 
plasminogen into angiostatin-like fragments 
(Heidtmann et al. 1999). However, we 
showed that highly purified and active PSA 
is not able to cleave plasminogen or to 
produce angiostatin; we tested several 
plasminogen preparations from different 
manufacturers and several batches of PSA 
(V). Moreover, we did not find any 
measurable concentrations of angiostatin in 
the cell culture medium collected from 
HUVEC tube formation assays with and 
without PSA. We used an ELISA 
immunoassay, the sensitivity of which is 
enough to measure 100-fold lower levels of 
angiostatin than those needed for inhibition 
of tube formation and 10-fold lower levels 
than needed for inhibition of migration 
(Gately et al. 1997; Claesson-Welsh et al. 
1998). The cell culture medium samples 
were also tested by an ELISA immunoassay 
for another antiangiogenic molecule, 
endostatin, but PSA did not increase its 
levels in the HUVEC tube formation assay. 
Thus, the mechanism by which PSA inhibits 
angiogenesis in the HUVEC model is most 
likely not due to generation of neither 
endostatin nor angiostatin.  
Notably, the reported cleavage site in 
plasminogen after glutamic acid has not been 
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described for PSA with any other substrate 
and the cleavage site after lysine is not 
favored by PSA either, according to the 
peptidase database MEROPS (Heidtmann et 
al. 1999; Rawlings et al. 2012). Instead, the 
cleavage after lysine is typical for trypsin-
like enzymes (Barrett et al. 2004; Rawlings 
et al. 2012). As mentioned earlier, the purity 
of PSA preparations used in different studies 
may vary due to differences in purification 
method. Therefore, caution is needed when 
evaluating studies on the substrates of PSA. 
PSA preparations may contain several highly 
active proteases that are produced by the 
prostate, including trypsin and other KLKs 
(Paju et al. 2000; Koistinen et al. 2002; Shaw 
and Diamandis 2007) and it is possible that 
small amounts of contaminating proteases in 
a PSA preparation cause effects that will be 
incorrectly ascribed to PSA. Several MMPs 
and elastase (reviewed in Cao and Xue 
2004), uPA and tPA (Gately et al. 1997) and 
also several KLKs with trypsin-like activity, 
such as KLK5 (Michael et al. 2006), KLK6 
(Bayes et al. 2004) and KLK13 (Sotiropou-
lou et al. 2003), have been reported to 
generate angiostatin-like fragments from 
plasminogen. The trypsin-like KLK5 cleaves 
the same Lys77-Lys78 peptide bond in 
plasminogen that is reported to be cleaved by 
PSA (Heidtmann et al. 1999; Michael et al. 
2006). In another study, both recombinant 
PSA and KLK5 were reported to produce 
active plasmin from plasminogen, as 
measured by a chromogenic substrate for 
plasmin, but not to release any angiostatin-
like fragments (de Souza et al. 2013).  
  
3.1 PSA-induced changes in HUVEC 
gene expression (IV) 
To further characterize the mechanism of the 
antiangiogenic activity of PSA in the 
HUVEC tube formation model, changes in 
PSA-induced gene expression were analyzed 
by a DNA microarray. The changes found 
were of small scale, but possibly 
physiologically significant. As changes in 
the expression of single genes may not be 
sufficient to reveal the presumably complex 
mechanism of the antiangiogenic activity of 
PSA, the differentially expressed genes were 
also analyzed for enrichment in different 
pathways. These genes were found to be 
enriched in several pathways that are thought 
to be relevant for the morphological 
differentiation of endothelial cells during 
tube formation, for protein translation and 
for proteolytic processes. Changes in the 
expression of genes involved in zinc ion 
binding were also observed. However, the 
pathway analysis did not give exact 
information about the mechanism of the 
antiangiogenic activity of PSA.   
Gene expression changes associated 
with normal tubulogenesis (Glesne et al. 
2006; Cooley et al. 2010) and angiogenesis 
(Cline et al. 2002; Schoenfeld et al. 2004; 
Chen et al. 2006) have been reported in 
studies on endothelial cells grown either on 
Matrigel or on plastic surface. When these 
were compared to our microarray data, we 
found that the gene expression changes 
induced by PSA treatment were opposite to 
those associated with normal tubulogenesis 
(Glesne et al. 2006), which was expected as 
PSA inhibits tube formation. However, there 
was no correlation with changes in angiogen-
esis-related gene expression induced by 
treatment with growth factors that stimulate 
angiogenesis (Schoenfeld et al. 2004) or with 
angiostatin and endostatin that inhibit it 
(Cline et al. 2002).  
PSA has been shown to induce angio-
genesis-related gene expression changes in 
prostate cancer cells, as it down-regulates the 
expression of proangiogenic VEGF and 
uPA, and up-regulates the expression of 
interferon-γ involved in angiogenesis 
inhibition (Bindukumar et al. 2005; 
Bindukumar et al. 2008). As the PSA-
induced changes in gene expression 
observed in the present study were small, the 
effect of PSA on tube formation might not 
primarily be caused by the changes in gene 
expression, but rather be associated with the 
proteolytic activity of PSA. The gene 
expression changes observed may be 
secondary to this. 
The microarray data could not be fully 
validated by RT-PCR. Of the five genes 
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selected for validation, one showed similar 
differential expression with statistical 
significance, while three other genes showed 
only a similar trend as in the microarray. 
Thus, these results have to be considered as 
preliminary and need further validation. 
However, we did not pursue validation, as 
the gene expression changes were small and 
we considered it unlikely that the mechanism 
of the antiangiogenic activity of PSA 
operates through changes in the gene 
expression.  
 
3.2 Significance of the antiangiogenic 
activity of PSA  
The antiangiogenic activity of PSA suggests 
that PSA may prevent or slow down the 
growth of prostate cancer. However, PSA 
also exerts activities that may promote tumor 
growth and metastatic dissemination. Other 
KLKs (such as KLK2, 5, 6 and 13) have been 
suggested to affect cancer growth, e.g., by 
degradation of ECM proteins (Deperthes et 
al. 1996; Magklara et al. 2003; Kapadia et al. 
2004; Michael et al. 2006).  
When prostate cancer can be detected on 
the basis of increased serum PSA levels 
(> 4 µg/L), the tumor weighs about 0.5 – 1 g 
and thereafter it usually grows very slowly, 
with a doubling time of 2 to 3 years, as 
determined by PSA levels, which correlate 
with the tumor volume (Schmid et al. 1993; 
Stenman et al. 1994). After this it may take 5 
to 10 years before the disease surfaces 
clinically and more than 10 to 15 years 
before it threatens the life of the patient, 
unless cured by radical therapy (Stenman et 
al. 1994; Bill-Axelson et al. 2014). 
Assuming that prostate cancer grows at a 
constant doubling time of 2 years to reach the 
size of 1 g, it would take over 50 years, as a 
single tumor cell would need to double about 
27 times (Stenman et al. 1999a; Stenman 
1997; Del Monte 2009). Obviously, the 
tumor has to grow more rapidly before 
reaching this size. However, the growth of 
prostate cancer usually slows down after this 
initial rapid growth period. When a tumor 
reaches a size of ~ 1 mm3 (about 16 -17 
doublings), it requires a vasculature to grow 
further (Hanahan and Folkman 1996; 
Folkman 2006). The switch to slow growth 
could result from the antiangiogenic activity 
of PSA (Stenman et al. 2000; Koistinen and 
Stenman 2012). The lowest PSA concentra-
tions at which the antiangiogenic effect was 
significant in our study in vitro, were of an 
order of magnitude lower than the concentra-
tions measured in the extracellular fluid of 
the prostate (Denmeade et al. 2001). 
Already in men under 40 years of age, 
serum PSA levels may predict an increased 
risk of prostate cancer. Higher PSA concen-
trations can be detected in men that develop 
prostate cancer 25 to 35 years later than in 
men that do not develop prostate cancer 
(Whittemore et al. 2005; Lilja et al. 2011). 
Men of this age may already have micro-
scopic tumors, but these tumors are so small 
that they are not likely to raise serum PSA. 
Thus, it is possible that increased circulating 
PSA levels may, instead of just being a 
consequence of tumor development, reflect 
the involvement of PSA in the early 
development of prostate cancer, e.g., by 
digestion of IGFBP-3 and release of IGF-I, 
which is a potent growth factor associated 
with prostate cancer (Cohen et al. 1994). 
PSA has also been shown to increase 
proliferation and to reduce apoptosis of 
prostate cancer cells (Niu et al. 2008; 
Williams et al. 2011). The expression of PSA 
in the prostate of transgenic mice has not 
been found to initiate prostate cancer or to 
cause any morphological changes in the 
prostate (Williams et al. 2010). However, the 
concentrations of PSA in the prostate of 
these mice were up to 1000-fold lower than 
those in the human prostate (Denmeade et al. 
2001; Williams et al. 2010).  
At later stages, when the tumor needs 
vascularization, PSA may inhibit or slow 
down tumor growth by its antiangiogenic 
activity. This dual function would explain 
why prostate cancer, on the one hand, is so 
common and, on the other hand, grows so 
slowly at the stage, when it can be detected 
on the basis of an increased PSA. Indeed, 
similar dual functions, involving both cancer 
growth-promoting and cancer growth-
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inhibiting activities related to the cancer type 
or stage have been suggested also for KLK6 
and KLK10 (Zhang et al. 2006; Klucky et al. 
2007; Sotiropoulou and Pampalakis 2012).  
Several clinical studies have shown that 
PSA may have a tumor suppressive effect: 
low tissue PSA concentrations as well as low 
PSA expression are associated with aggres-
sive cancer and an adverse prognosis 
(Abrahamsson et al. 1988; Pretlow et al. 
1991; Magklara et al. 2000; Stege et al. 2000; 
Paju et al. 2007). Also, high PSA expression 
has been found to be associated both with 
reduced microvessel density (Papadopoulos 
et al. 2001) and low angiogenesis activity, as 
detected by a CD34 antibody in prostate 
cancer tissue (Ben Jemaa et al. 2010). In this 
context, it should be stressed that the PSA 
expression and protein levels in the prostate 
do not correlate with circulating PSA levels 
in cancer patients, as the latter are increased 
due to leakage of PSA into circulation and 
not due to higher expression, while the 
expression of PSA in cancer is decreased as 
compared to normal prostate (Abrahamsson 
et al. 1988; Paju et al. 2007). Also the 
enzymatic activity of PSA in prostatic fluid 
was shown to be inversely associated with 
the aggressiveness of prostate cancer 
(Ahrens  et al. 2013).  This  further  supports
the relevance of the proteolytic activity of 
PSA during cancer growth. 
Due to its highly prostate-specific 
expression and antiangiogenic properties, 
PSA is a potential therapeutic target for 
prostate cancer. PSA-stimulating peptides, 
in addition to being useful research tools for 
studying the proteolytic activity of PSA, may 
also be useful lead molecules for develop-
ment of novel treatments and imaging agents 
for prostate cancer. Stimulation of the anti-
angiogenic activity of PSA may delay the 
development of clinical disease and may be 
sufficient for preventing the cancer from 
surfacing clinically within the lifetime of the 
patient.  
Although the molecular mechanism 
behind the antiangiogenic activity of PSA 
could not be identified, the present study 
provides a good basis for further studies. We 
showed that the antiangiogenic effect is 
mediated in the cell culture medium after 
inactivation of the proteolytic activity of 
PSA and ruled out the most obvious 
mediators, angiostatin and endostatin. The 
mediators of the antiangiogenic activity of 
PSA would be feasible to study directly or 
after fractionation of the cell culture medium 
by proteomic methods, such as 2D-PAGE or 
mass spectrometry. 
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SUMMARY AND CONCLUSIONS 
This thesis work characterized the antiangio-
genic and proteolytic activities of PSA. The 
proteolytic activity of PSA toward different 
peptide and protein substrates was examined. 
The major physiological substrates, semeno-
gelins, were shown to be degraded by PSA 
much more rapidly than any other of protein 
substrates studied. Nidogen-1, a protein of 
the basement membrane, was identified as a 
novel substrate for PSA. Peptides that 
stimulate PSA enhanced its proteolytic 
activity differently toward peptide substrates 
and protein substrates: the stimulating 
peptide with less efficient stimulation with 
peptide substrates was more efficient with 
protein substrates. 
PSA exerted antiangiogenic activity in a 
dose-dependent fashion in the HUVEC tube 
formation assay. Based on the experiments 
with active and inactive forms of PSA, the 
antiangiogenic activity was shown to be 
dependent on the enzymatic activity of PSA. 
Accordingly, the antiangiogenic effect was 
enhanced by peptides that stimulated the 
enzymatic activity of PSA and abolished by 
small molecule compounds and a monoclo-
nal antibody that inhibited PSA activity.  
To study the molecular mechanism of the 
antiangiogenic activity of PSA, the PSA-
induced changes in HUVEC gene expression 
during tube formation were determined. 
Most of the gene expression changes were 
minor and it was not possible to elucidate if 
these changes were primary or secondary to 
the antiangiogenic activity. Further experi-
ments with the tube formation assay 
corroborated the view that the antiangio-
genic activity of PSA may be mediated by a 
proteolytic cleavage product of PSA. This 
proteolytic fragment is, for the moment, 
elusive. However, the antiangiogenic 
activity of PSA was not mediated by 
angiostatin-like fragments generated by the 
cleavage of plasminogen, as assumed earlier.  
As the expression of PSA is mainly 
prostate-specific, with high concentrations 
of active PSA being present in the prostate 
cancer microenvironment, PSA could serve 
as a therapeutic target for prostate cancer. 
Peptides that stimulate the activity of PSA 
could be useful for reducing tumor 
angiogenesis and for inhibiting prostate 
cancer growth. 
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